WO2012080116A1 - Producing unacetylated sophorolipids by fermentation - Google Patents

Producing unacetylated sophorolipids by fermentation Download PDF

Info

Publication number
WO2012080116A1
WO2012080116A1 PCT/EP2011/072304 EP2011072304W WO2012080116A1 WO 2012080116 A1 WO2012080116 A1 WO 2012080116A1 EP 2011072304 W EP2011072304 W EP 2011072304W WO 2012080116 A1 WO2012080116 A1 WO 2012080116A1
Authority
WO
WIPO (PCT)
Prior art keywords
sophorolipids
acetyltransferase
candida
unacetylated
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/072304
Other languages
French (fr)
Inventor
Karen Saerens
Inge Van Bogaert
Wim Soetaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Original Assignee
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent filed Critical Universiteit Gent
Publication of WO2012080116A1 publication Critical patent/WO2012080116A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • C12N1/165Yeast isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • C12P19/445The saccharide radical is condensed with a heterocyclic radical, e.g. everninomycin, papulacandin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi
    • C12R2001/72Candida

Definitions

  • Unacetylated sophorolipids show interesting applications in several industrial fields but cannot be produced in a pure and straight way by conventional fermentation.
  • the present invention discloses the production of entirely unacetylated sophorolipids without acetylated variants by fermentation. More specifically, the present invention discloses a yeast strain which is mutated in a gene encoding for an acetyltransferase and which is capable of producing a mixture of entirely unacetylated sophorolipids. Preferably, the majority within said mixture are unacetylated lactonic sophorolipids.
  • the acetyltransferase of the present invention can be used to acetylate carbohydrates or carbohydrate-containing compounds.
  • the non-pathogenic yeast Candida (Starmerella) bombicola ATCC 22214 (CBS 6009) is commercially applied for the production of sophorolipids.
  • These glycolipid biosurfactants are constituted of a sophorose head group (2-0 ⁇ -D-glucopyranosyl-D-glucopyranose) attached to a (sub)terminal hydroxylated Ci 8 or Ci 6 fatty acid and this by a glycosidic linkage between the anomeric C-atom of the sugar and the hydroxylgroup of the fatty acid.
  • Sophorolipids are typically produced by fermentation in presence of a hydrophobic carbon source and are always constituted of a mixture of structurally related molecules with variation in 1) degree of fatty acid saturation (saturated, mono-unsaturated or di- unsaturated), 2) presence of acetylgroups at C6' and/or C6" atoms, 3) lactonization between the carboxyl end of the fatty acid and either the C4", C6' or C6" atom of the sophorose group, 4) fatty acid chain length and 5) ( ⁇ ) or ( ⁇ -1) hydroxylation of the fatty acid (Asmer ef a/., 1988).
  • sophorolipids show many interesting applications in a wide range of industrial fields (Banat et al., 2010; Franzetti et al., 2010; Kralova and Sjoblom, 2009; Mulligan, 2009). Since structural composition is reflected in the physico-chemical properties, several industries are particularly interested in specific structural variants. Acetylation is one structural feature that gains a lot of attention especially because of its contribution to biological activity in addition to its influence on water solubility and foaming properties. The decreased cytotoxicity of unacetylated sophorolipids as compared to acetylated variants for example has attracted attention to use these molecules as new antiviral drugs (Shah et al., 2005).
  • dispersible nanoparticles and glycolipid derivatives (Azim et al., 2006; Zerkowski et al., 2006) or have served as source molecules for the production of glucolipids and specialty fatty acids (Rau et al., 2001 ; Saerens et al., 2009), which are on their turn used for synthesis of polymers (Zerkowski et al., 2007) or precursors for plastics and flavours (Rau et ai, 2001).
  • An alternative way to obtain entirely unacetylated variants would be to prevent acetylation within the sophorolipid-producing organism, e.g. through mutations in or deletions of their acetylating enzymes.
  • Several fungal genomes contain multiple (putative) O- acetyltransferase genes and the specific activity of an O-acetyltransferase is hard to predict based on the amino acid sequence, resulting in a lot of these sequences only being marked as "putative" O-acetyltransferase without any information on the specific action. For instance, in the genome of C.
  • the present invention provides a nucleic acid molecule consisting of the sequence as depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • the invention provides a polypeptide consisting of the amino acid sequence as depicted by SEQ ID N° 2 and having acetyltransferase activity, or a fragment thereof retaining said acetyltransferase activity, or a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • the invention further provides the use of a nucleic acid molecule as defined above having lost its capability to encode for a functional acetyltransferase, or, the use of a polypeptide as defined above having lost its acetyltransferase activity to produce a mixture comprising entirely unacetylated sophorolipids.
  • the present invention provides a the use of a fungal species which is capable of producing sophorolipids to produce a mixture comprising entirely unacetylated sophorolipids wherein said fungal species has at least one mutation in a nucleic acid molecule defined above and wherein said mixture comprises at least 50% of entirely unacetylated sophorolipids.
  • said nucleic acid molecule is depicted by SEQ ID N° 1 encoding for an acetyltransferase, or is a fragment thereof encoding for a protein retaining said acetyltransferase activity, or is a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • the invention further provides methods of producing a mixture comprising entirely unacetylated sophorolipids, using a nucleic acid molecule as defined above having lost its capability to encode for a functional acetyltransferase, or, the use of a polypeptide as defined above having lost its acetyltransferase activity.
  • said method comprises the steps of: a) providing a host cell comprising the nucleic acid molecule or polypeptide as defined above, and b) allowing said host cell to produce sophorolipids using standard culturing techniques.
  • said sophorolipids can be isolated or purified from the cell culture.
  • Said host cell can be a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
  • said entirely unacetylated sophorolipids comprises at least or equal to 70% of lactonic sophorolipids.
  • said yeast species is selected from the group consisting of Candida bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellata, Candida sp. NRRL Y-27208, Rhodotorula bogoriensis, Wickerhamiella domericqiae and sophorolipid-producing species of the Starmerella clade.
  • said Candida bombicola is the strain Candida (Starmerella) bombicola ATCC 22214.
  • said mutation is a deletion and/or insertion and said deletion and/or insertion results in a non-functional polypeptide.
  • the invention further provides a modified yeast strain belonging to a fungal species capable of producing sophorolipids, characterized in that said fungal strain, compared to an unmodified wild type strain: a) has at least one mutation in a nucleic acid molecule as defined above, and b) produces a mixture of entirely unacetylated sophorolipids comprising at least 50% of entirely unacetylated sophorolipids.
  • said nucleic acid molecule is depicted by SEQ ID N° 1 encoding for an acetyltransferase, or is a fragment thereof encoding for a protein retaining said acetyltransferase activity, or is a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • the invention further provides for the use of a polypeptide having acetyltransferase activity as defined above to acetylate carbohydrates or carbohydrate-containing compounds.
  • said polypeptide consists of the amino acid sequence as depicted by SEQ ID N° 2 and has acetyltransferase activity, or is a fragment thereof retaining said acetyltransferase activity, or is a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • the invention further provides for methods for acetylating carbohydrates or carbohydrate- containing compounds, using a polypeptide having acetyltransferase activity as defined above.
  • the invention further provides for the use of a modified host strain expressing a polypeptide having acetyltransferase activity as defined above to acetylate carbohydrates or carbohydrate-containing compounds.
  • said polypeptide consists of the amino acid sequence as depicted by SEQ ID N° 2 and has acetyltransferase activity, or is a fragment thereof retaining said acetyltransferase activity, or is a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • the invention further provides for methods of acetylating carbohydrates or carbohydrate- containing compounds, using the modified host strain expressing a polypeptide having acetyltransferase activity as defined above.
  • said modified host strain is transformed with an exogenous nucleic acid molecule as defined above or said modified host strain over-expresses an endogenous nucleic acid molecule as defined above.
  • said nucleic acid molecule is depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • said modified host strain is a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
  • yeast is Candida (Starmerella) bombicola ATCC 22214.
  • Fig. 1 The major-but not the sole- components of the new sophorolipid mixture of the present invention.
  • entirely unacetylated lactonic 17- and 18-O-sophorosyl-octadecenoic acid were the most predominant structures (a,b), in addition to entirely unacetylated lactonic 17-O-sophorosyl- octadecanoic acid (c) and acidic 17-O-sophorosyl-octadecenoic acid (d).
  • Fig. 2 Sophorolipids typically produced during fermentation are considered to be a mixture of compounds represented by formulas a) acidic form and b) lactonic form.
  • Fig. 4 Alignment of the C. bombicola acetyltransferase sequence with five model sequences that define the conserved domain of Lbh_MAT-GAT subfamily proteins. The 30 conserved amino acids from the active site are indicated by arrows.
  • 731964 putative acetyltransferase YJL218W Saccharomyces cerevisiae
  • 158333766 putative maltose O-acetyltransferase Acaryochloris marina MBIC 11017
  • 27552460 putative O-acetyltransferase Physcomitrella patens
  • 76803978 putative maltose O- acetyltransferase Vibrio sp. DAT 722
  • 23466264 thiogalactoside acetyltransferase Bifidobacterium long urn NCC 2705.
  • Fig. 6 Colony forming units for C. bombicola ATCC 22214 (filled circles) and the Aat deletion mutant (filled squares). Rapeseed oil was added after 48 hours of incubation (arrow).
  • Fig 8. Optical density (OD) and glucose consumption for the Aat deletion mutant (AT3) and wild type C. bombicola ATCC22214 (WT) cultivated in a 2L Biostat reactor. Additional glucose (30 g/L) was added to the wild type cultivation after 140 hours. Rapeseed oil (approximately 30 g/L) was added stepwise at 28h, 52h and 117h to AT3 and at 46h, 65h and 140h to WT.
  • Panel A: "Reference” standard sophorolipid production medium as described by Lang et al.
  • Fig 11. AT overexpression construct (A), mutant Aura3 locus of the i/ra3-negative C. bombicola (B) and resulting genotype of the AT overexpressing mutant after homologous recombination and double cross-over between the mutated ura3 locus and the construct (C). Primer sites are indicated and regions used for homologous recombination are highlighted by dotted lines.
  • Fig 12. Growth (CFU) and glucose consumption for the AT-overexpressing C. bombicola (AT+78CM) and C. bombicola ATCC2214 (WT) cultivated in a 2L Biostat reactor.
  • the present invention discloses the identification of a single acetyltransferase gene AT from Candida (Starmerella) bombicola which is fully responsible for the acetylation of sophorolipids. Deletion of the gene surprisingly results in a yeast species producing only unacetylated sophorolipids (see Figure 1). Moreover, under the standard fermentation conditions the lactonic unacetylated sophorolipids are the predominant molecules in the mutant mixture (see Figure 1). Wth this new structural composition, the created mutant offers a one-step production technology for the fermentative synthesis of industrially important molecules making use of cheap, renewable substrates. Up to date, it was not possible to produce a sophorolipid mixture with this structural composition.
  • the identification of the AT gene as the single gene responsible for acetylation of sophorolipids enables the creation of an overexpression mutant where diacetylated sophorolipids are remarkably enriched thus with the mutant mixture being deprived from mono- and unacetylated sophorolipids. Because the significant increase in antibacterial (Gross and Shah, 2004), antifungal (Gross and Shah, 2005) and antiviral (Shah et a/., 2005) activity of diacetylated sophorolipids as compared to mono- or unacetylated variants, such mutant mixture attracts attention of pharmaceutical and medical industries.
  • the present invention thus relates to the usage of a fungal species which is capable of producing sophorolipids to produce a mixture of entirely unacetylated sophorolipids wherein said fungal species has at least one mutation in a nucleic acid molecule of the present invention encoding for an acetyltransferase of the present invention and wherein said mixture comprises at least 50% of unacetylated sophorolipids.
  • the present invention further preferably relates to the usage as indicated above wherein the majority (i.e. more or equal than 70%) within said mixture are lactonic, unacetylated sophorolipids.
  • the term 'fungal species capable of producing sophorolipids' refers to a phylogenetically diverse group of yeasts (predominantly Ascomycetes and few Basidiomycetes) which spontaneously synthesize sophorolipids constituted of the sugar sophorose attached to a hydroxylated fatty acid (see Figure 2).
  • Said phylogenetically diverse group of yeasts comprises the species Candida apicola (Gorin et al., 1961) which was initially identified as C. magnolia, C.
  • the term 'wherein said fungal species has at least one mutation in a nucleic acid molecule of the present invention encoding for an acetyltransferase of the present invention' refers to a modified yeast species or yeast strain characterized in having at least one mutation in a nucleic acid molecule of the present invention encoding for an acetyltransferase of the present invention.
  • the term 'mutation' refers to a spontaneous mutation and/or to an induced mutation in the genome of said yeast strain. Said mutation can be a point mutation, deletion, insertion or any other type of mutation. The term most specifically refers to knock outs (KO) via insertion of a KO cassette.
  • Inducing a mutation in the genome of a yeast strain can be undertaken by any method in the art known by a skilled person such as the insertion of a KO cassette into a gene of interest.
  • tracing or detecting whether there is a mutation in the genome of a modified strain -compared to a wild type strain- can also be done by any method known in the art.
  • 'sophorolipids' refers to carbohydrate-based, amphiphilic biosurfactants that are constituted of the sugar sophorose attached to a hydroxylated fatty acid/alkyl chain, i.e. hydroxylated fatty acid/alkyl chains wherein the fatty acid/alkyl chain contains 5 to 26 carbon atoms.
  • a hydroxylated fatty acid/alkyl chain i.e. hydroxylated fatty acid/alkyl chains wherein the fatty acid/alkyl chain contains 5 to 26 carbon atoms.
  • Preferably -and especially with regard to C. bombicola- said fatty acid chain is composed of 16 or 18 C-atoms.
  • glycolipid biosurfactants that are constituted of a sophorose head group (2- ⁇ - ⁇ - ⁇ - glucopyranosyl ⁇ -D-glucopyranose) from which the anomeric C-atom is attached to an ( ⁇ ) or ( ⁇ -1) hydroxylated C 10 , C 12 , C M , Ci 6 , Ci 8 , C 22 or C 24 fatty acid. They occur either as open-ring structures (acidic form) or as lactones (closed-ring structures or lactonic form or lactonised form) with an intra-esterification between the fatty acid carboxyl group and the 4", 6' or 6" carbon atom of the sophorose head group.
  • acetyl groups can be attached at the 6' and/or 6" positions (Asmer et al., 1988).
  • 'unacetylated sophorolipids' refers to sophorolipids without acetylgroups at the C6' and C6" atoms.
  • a mixture comprising at least 50% of unacetylated sophorolipids' refers to a mixture which is less complex (as shown in Figure 1) as compared to the mixture which one obtains in a typical wild type Candida bombicola fermentation (Asmer et al., 1988). Indeed the mixture of the present invention is deprived from acetylated forms. In other words, no acetylated forms can be detected -using well-known methods- in the mixture of the present invention.
  • the mixture of the present invention comprises at least 50%, i.e. 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100% of unacetylated sophorolipids.
  • said mixture of the present invention comprises -or can consist of- a majority of unacetylated lactonic sophorolipids (i.e. more or equal than 70%) and a minority of unacetylated acidic sophorolipids (less than 30%). This lactonic:acidic ratio of unacetylated sophorolipids (i.e.
  • bombicola fermentation on glucose and oleic acid 62% is composed of diacetylated lactonic forms, 4% is composed of monoacetylated lactonic forms and 4% is composed of unacetylated lactonic forms while the other compounds are constituted of 1 ',6' lactones and 1',6" lactones (4%), acidic sophorolipids (8%) and other lipids at the end of the cultivation period (Asmer et al., 1988).
  • Hu and Ju (2001 b) observed a maximum relative percentage of lactonic forms of 50% using soybean oil and 80% using hexadecane.
  • Yeast extract concentration and presence of citric acid influence the ratio of lactonic to acidic sophorolipids too: when yeast extract concentration was 1 g/L, 65% of sophorolipids were in lactonic forms but when the concentration was increased to 20 g/L, all sophorolipids were in acidic form (Casas and Garcia-Ochoa, 1999). Addition of 5 g/L of citric acid to the medium increased the percentage of lactonic forms in the sophorolipid mixture of Candida apicola (Hommel et al., 1994).
  • the present invention further specifically and preferably relates to the usage as described above wherein said mixture comprises at least or equal to 70% of lactonic, unacetylated sophorolipids.
  • yeast species is selected from the group consisting of Candida bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellata, Candida sp. NRRL Y-27208, Rhodotorula bogoriensis, Wickerhamiella domericqiae and sophorolipid-producing species of the Starmerella clade.
  • the present invention relates to the usage as described above, wherein said Candida bombicola is the strain Candida bombicola ATCC 22214 (CBS 6009).
  • the present invention also relates to a modified fungal strain belonging to a fungal species capable of producing sophorolipids as described above, characterized in that said fungal strain, compared to an unmodified wild type strain : a) has at least one mutation in the gene encoding for the acetyltransferase of the present invention , and b) produces a mixture comprising at least 50% entirely unacetylated sophorolipids.
  • the present invention relates to the usages as described above, wherein said mutation is a deletion in the acetyltransferase of the present invention..
  • the present invention thus relates to a nucleic acid sequence as depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • SEQ ID N° 1 corresponds to the following open reading frame of 780 base pairs:
  • nucleic acid' and a 'fragment' or a 'variant' thereof corresponds for example to DNA, cDNA, RNA, sense and anti-sense nucleic acids and the like.
  • fragment' specifically refers to a nucleic acid sequence containing fewer nucleotides than the nucleic acid sequence as depicted by SEQ ID N° 1 and that encodes for a protein retaining said acetyltransferase activity.
  • variant specifically refers to a nucleic acid encoding for a protein having at least 50 % sequence identity, preferably having at least 51-70 % sequence identity, more preferably having at least 71-90% sequence identity or most preferably having at least 91 , 92, 93, 94, 95, 96, 97, 98 or 99 % sequence identity with SEQ ID N° 2 (see further) or with a fragment thereof, and, that encodes for a protein retaining said acetyltransferase activity.
  • a specific, but non-limiting example of a fragment of the present invention is a fragment that encodes for the amino acid sequence having SEQ ID N° 13 which corresponds to the following sequence:
  • a specific, but non-limiting example of a fragment of the present invention encoding the amino acid sequence having SEQ ID N°13 is the following nucleic acid sequence (SEQ ID N°14): 1 atgactccta gaaaagaaat tgaccaggaa atggtctctt gggccaaaaa aaacctcaaa
  • the present invention further relates to an amino acid sequence as depicted by SEQ ID N° 2 having acetyltransferase activity, or a fragment thereof retaining said acetyltransferase activity or a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
  • SEQ ID N° 2 corresponds to the following 259 amino acids (given by the one-letter code of amino acids):
  • fragment' refers to a protein (or peptide or polypeptide) containing fewer amino acids than the amino acid sequence as depicted by SEQ ID N° 2 and that retains said acetyltransferase activity.
  • Such fragment can -for example- be a protein with a deletion of 10% or less of the total number of amino acids at the C- and/or N-terminus.
  • a specific example is indicated by SEQ ID N° 13.
  • variant refers to a protein having at least 50 % sequence identity, preferably having at least 51-70 % sequence identity, more preferably having at least 71-90% sequence identity or most preferably having at least 91 , 92, 93, 94, 95, 96, 97, 98 or 99 % sequence identity with SEQ ID N° 2 or with a fragment thereof, and, that encodes for a protein retaining said acetyltransferase activity.
  • orthologues or genes in other genera and species (than the strain Candida bombicola ATCC 22214 from which SEQ ID N° 1 and 2 are derived; with at least 50% identity at amino acid level, and having the described function are part of the present invention.
  • the percentage of amino acid sequence identity is determined by alignment of the two sequences and identification of the number of positions with identical amino acids divided by the number of amino acids in the shorter of the sequences x 100.
  • the latter 'variant' may also differ from the protein as depicted by SEQ ID N° 2 only in conservative substitutions and/or modifications, such that the ability of the protein to have acetyltransferase activity is retained.
  • a “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of protein chemistry would expect the nature of the protein to be substantially unchanged.
  • the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
  • Variants may also (or alternatively) be proteins as described herein modified by, for example, the deletion or addition of amino acids that have minimal influence on the acetyltransferase activity as defined above, secondary structure and hydropathic nature of the enzyme.
  • the present invention further relates to the usage of a nucleic acid molecule as defined above having lost its capability to encode for a functional acetyltransferase, or, to the usage of a polypeptide as defined above having lost its acetyltransferase activity to produce a mixture comprising entirely unacetylated sophorolipids.
  • a nucleic acid molecule having lost its capability to encode for a functional acetyltransferase as defined above can be obtained by mutation or by any known means to silence the transcription or translation of said nucleic acid such as the insertion of a nucleic acid fragment, a marker gene or others in the functional coding or non-coding part of the acetyltransferase gene, a mutation or removal of the functional coding or non-coding part of the acetyltransferase gene, the usage of specific siRNAs, miRNAs, combinations hereof or any other way.
  • a polypeptide as defined above having lost its acetyltransferase activity can be obtained by any (small) compound or other means to disrupt the function of the acetyltransferases of the present invention.
  • Means to silence the transcription or translation or means to disrupt the function of the acetyltransferase of the present invention or means to disrupt the function of a necessary regulator/activator protein of the acetyltransferase thus comprise the usage of any molecule such as -but not limited to- an antibody, an amino acid, a peptide, a small molecule, an aptamer, a ribozyme, an oligoribonucleotide sequence such a dsRNA used to initiate RNA interference (RNAi) or an anti-sense nucleic acid.
  • RNAi RNA interference
  • Such a molecule is thus capable to bind on a acetyltransferase protein or an activator/regulator protein thereof or is capable to interfere with the cellular synthesis of acetyltransferase or of an activator/regulator thereof by -for example- binding and degrading mRNA's encoding for an acetyltransferase protein or an activator/regulator thereof.
  • the present invention further relates to the usage of the proteins/polypeptides/peptides having acetyltransferase activity as described above to acetylate carbohydrates or carbohydrate-containing compounds such as sophorolipids, cellobioselipids, alkylglucosides, etc..
  • the present invention relates to the usage of a modified host strain expressing a protein having acetyltransferase activity as described above to acetylate carbohydrates or carbohydrate-containing compounds.
  • the present invention relates to the usage as described above wherein said modified host strain is transformed with an exogenous nucleic acid sequence as described above or wherein said modified host strain over-expresses an endogenous nucleic acid sequence as described above.
  • said modified host strain is a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
  • C. bombicola ATCC 22214 (CBS 6009) was maintained on YPD medium containing 1 % yeast extract, 2% peptone, 2% dextrose and 2% agarose and incubated at 30°C.
  • C. bombicola was shifted to 3C medium containing 10% glucose, 1 % yeast extract, 0.1 % urea and 2% agarose before inoculation to liquid production medium described by Lang et al. (2000).
  • Liquid media were incubated at 30°C and 200 rpm for two days before addition of rapeseed oil (37.5 g/L).
  • Escherichia coli DH5oc F' was used for plasmid maintenance and grown on Luria Bertani medium (0.5% Bacto yeast extract, 1 % Bacto Trypton, 0.5% NaCI) containing 0.01 % ampicillin and incubated at 37°C and 200 rpm. Plasmids were isolated by means of the MiniPrep Plasmid Isolation kit from Qiagen and sequenced at AGOWA (Germany).
  • a frameshift was induced in the AT gene by digesting plasmid pGATtot overnight with the single cutter So/I I (New England Biolabs) according to Sambrook (Sambrook and Russell, 2001) resulting in linearization after bp 169 of the AT gene.
  • the linearized plasmid was purified by means of the QIAquick® PCR purification kit from Qiagen and 1.77 ⁇ g was subjected to 2U Mung Bean Exonuclease (New England Biolabs) to remove the 5' overhangs. Incubation occured at 30°C for 30 minutes.
  • Plasmid 10 referred to as pGATtot mutATI O, was chosen for further consideration.
  • telomere sequence For integration of the hygromycin resistance marker into pGATtot mutATIO, the In-Fusion Dry Down PCR cloning kit (Clontech) was used. Linearisation of pGATtot mutATI O occurred by PCR with PfuUltra High Fidelity DNA polymerase (Stratagene) and primers KOATmutlOlinear inf F and KOATmutIO linear inf R (Table 1). Both primers anneal at the end of the mutated AT gene. A plasmid containing the hygromycin resistance marker in between tyrosine kinase (TK) terminator and C.
  • TK tyrosine kinase
  • bombicola GAPD promoter (Van Bogaert et al., 2008a) was used for amplification of the marker by means of primers KOATgapdhygro inf F and KOATgapdhygro inf R (Table 1). These primers each contain 15 bp of homology to the ends of the linearized plasmid pGATtot mutAT allowing subsequent fusion of both fragments.
  • the fusion product was called pGKOAT and cloned in E. Coli Fusion Blue competent cells (Invitrogen), insertion of the marker was verified by colony PCR and correct transformants were used for plasmid isolation as described above. Correctness of the insert was confirmed by sequencing.
  • a linear knock-out cassette was created from plasmid pGKOAT by PfuUltra High Fidelity DNA polymerase (Stratagene) making use of primers KOAT F and KOAT R (Table 1), the obtained 3742 bp fragment was purified by means of the QIAquick® PCR purification kit (Qiagen) and 688 ng was used for transformation of C. bombicola ATCC 22214 by electroporation. For that, the yeast was grown overnight in 100 ml YPD and when OD reached 1 , cells were harvested from 50 ml by centrifugation during 5 min at 4°C and 200 rpm.
  • the genotype of obtained mutants was checked by means of two yeast colony PCR reactions checking left- and right-sided homologous recombination with primer pairs KOATCtrl F/GAPD -775R and HygrolnsertCheck F/KOATCtrl R respectively (Table 1).
  • the reaction mix was composed of 1.25 U Standard Taq polymerase, 2.5 ⁇ reaction buffer and 200 ⁇ dNTP's (all from New England Biolabs) in addition to 400 ⁇ of each primer and milliQ water to a total volume of 25 ⁇ . A single colony was picked by means of a sterile needle and added to the reaction mixture.
  • PCR cycling program was set at 94°C for 7 minutes followed by 30 cycli of subsequently 94°C for 30 s, 54°C for 30 s and 72°C for 2.5 min, the latter having time increments of 5 s per cycle. Final elongation was performed at 72°C during 7 minutes.
  • the mutants were checked for sophorolipid production by growing them in Lang medium as described above.
  • C. bombicola ATCC 22214 served as a reference. Colony forming units and pH of the cultures were followed at regular time intervals throughout the whole experiment.
  • glucose concentrations were determined in the supernatant of 1 ml culture samples by means of HPLC-RI. Sophorolipid formation was checked 1 1 days after addition of rapeseed oil by means of HPLC-ELSD.
  • sophorolipid yields were obtained 19 days after addition of rapeseed oil by addition of 500 ⁇ acetic acid to each 50 ml culture and extracting three times with one volume of technical ethylacetate.
  • Solvent phases were poured together and evaporated to dryness. Residual oil was removed and quantified by washing the crude extract twice with 10 ml technical n-hexane and evaporating combined hexane phases to dryness. Purity of the extracts was checked by means of HPLC-ELSD.
  • Glucose samples were analysed on a Varian ProStart HPLC system equipped with an Aminex® HPX-87H ion exclusion column (300 mm x 7.8 mm) (Biorad) coupled to a LaChrom Rl detector (Merck). Column temperature was at 65°C and compounds were eluted in 25 minutes by means of a 5 mM H 2 S0 4 solution at a constant flow rate of 0.6 ml/min. Culture extracts were analysed for sophorolipid content on a Varian ProStar HPLC system equipped with a Chromolith® Performance RP-18e 100-4.6-mm column (Merck KGaA) and connected to an Evaporative Light Scattering Detector (Alltech).
  • a 1 L fermentation was set up with the C. bombicola Aat mutant AT3 and compared to the wild type yeast ATCC22214.
  • a 100 ml preculture in medium of Lang et al. (2000) was inoculated from a 3C agar plate (1.1.1) and grown overnight at 30°C and 200 rpm. This preculture was used as inoculum for 1 L fresh medium in a 2L benchtop BioStat fermentor (Sartorius Stedim Biotech, Germany).
  • 10% (v/v) sterile rapeseed oil was added to the preculture.
  • Aeration rate was 1 L/min, agitation speed 800 rpm and temperature set at 30°C.
  • Genome sequencing experiments with C. bombicola ATCC 22214 revealed a putative open reading frame of 780 bp with high homology to putative bacterial and fungal carbohydrate transacetylases, as shown by a blastx homology search to all non-redundant protein sequences available at the NCBI database (Altschul et al., 1997). Table 2 gives an overview of the ten best blastx-hits. Highest homology of 65% (47% sequence identity) is found to a putative protein from Clavispora lusitaniae ATCC 42720 (gb/EEQ36094). The putative C.
  • bombicola acetyltransferase of 259 amino acids had an estimated molecular mass of 28.6 kDa and estimated pi of 4.96.
  • the complete coding sequence is given in Figure 3.
  • the complete AT gene was submitted to GenBank under accession number HQ670751.
  • a deletion mutant was created from C. bombicola ATCC 22214. Recombination efficiency in C. bombicola is increased when double-sided homologous recombination can occur between the targetted genome locus and a linear DNA fragment of which both left- and right-sided flanks show around 1000 bp homology with the genomic sequence (Van Bogaert et al., 2008b).
  • a suitable knock-out cassette is usually based on the integration of a selectable marker between 1000 bp of the 5' and 3' ends of the gene that needs to be deleted.
  • the creation of the Aat deletion construct was started from plasm id pGATtot, a pGEM-T® derived plasmid harbouring the complete AT coding sequence (780 bp) in addition to 43 bp of the upstream and 2426 bp of the downstream sequences respectively. For that, first a frame- shift was introduced in the AT coding sequence to assure that homologous recombination between wild type AT locus and the construct would result in the replacement of the AT gene by a disfunctional at copy.
  • Figure 5 shows a schematic drawing of the wild type AT locus, the created knock-out construct and the Aat mutant locus after homologous recombination between construct and genome.
  • All three mutants showed equal growth as compared to the wild type yeast when grown in Lang medium with addition of rapeseed oil.
  • colony forming units were followed during cultivation and compared to the values obtained for the wild type yeast ( Figure 6).
  • glucose was completely depleted in both cultures.
  • Sophorolipid production was checked for all three mutants and the wild type yeast eleven days after addition of rapeseed oil, and the HPLC- ELSD chromatograms obtained showed that all three Aat deletion mutants produced identical sophorolipids which were clearly more polar as compared to those from the wild type yeast.
  • Figure 7 shows the HPLC-ELSD result from a culture extract from the Aat mutant AT4 and the corresponding masses as obtained by mass-spectrometric analysis. These masses confirm that only unacetylated sophorolipids were produced.
  • the extraction procedure might need some optimization for the new sophorolipid mixture (the culture supernatant still contained minor amounts of sophorolipids), the significant amount of residual oil indicates that conversion of rapeseed oil to unacetylated sophorolipids by the Aat deletion mutant occurs with lower efficiency as compared to native sophorolipid production by the wild type yeast. This might be explained by less efficient export of the unacetylated sophorolipids herewith delaying further synthesis of the compounds. Though the ABC transporter involved in secretion of cellobioselipids by U.
  • the created Aat deletion mutant produces mainly lactonic unacetylated sophorolipids. These are only produced in very minor amounts during conventional fermentation with C. bombicola or any other sophorolipid producing yeast species.
  • the created mutant thus produces a new and inventive sophorolipid mixture which is mostly constituted of unacetylated lactonic glycolipids.
  • sophorolipids are classified as low-foaming detergents, the unacetylated sophorolipid mixture of the mutant clearly showed increased foaming as was observed during extraction from the culture broth.
  • the lack of acetylgroups tremendously increases the water solubility of the product so that the unacetylated sophorolipids have unique properties that are of interest to several industries.
  • lactonic forms are the most predominant compounds in the mixture of the Aat deletion mutant and the fact that the ratio of lactonic to acidic sophorolipids in the mutant mixture is comparable to the wild type yeast indicates that the defectiveness of the acetylation function does not influence the lactonization pattern of the sophorolipids proving that acetylation is not a prerequisite for lactonization.
  • Unacetylated sophorolipids are of interest to several industries due to their different biological properties, foaming properties and better water solubility. For some applications, lactonic sophorolipids are preferable above acidic ones while for other industries the opposite might be true. Indeed, lactonization has a strong contribution to the overall polarity and chemical versatility of the sophorolipid. For wild type C. bombicola as well as for C. apicola, many papers have illustrated the effect of medium composition on the amount of acidic and lactonic sophorolipids (Casas and Garcia-Ochoa, 1999; Davila et al., 1992; Davila et al., 1994; Hommel et al., 1994; Hu and Ju, 2001 b).
  • sophorolipid lactonic:acidic ratio not only sophorolipid lactonic:acidic ratio, but also cell growth is affected by a change in yeast extract concentration or the omittment of citrate. Since yeast extract is rich in growth factors, a decrease in its concentration to 1 g/L results in an early delay of cell growth (and corresponding glucose consumption) as compared to the standard production medium with 4 g/L yeast extract. Surprisingly, sophorolipid production is comparable to the standard conditions indicating higher productivity of the cells and the same lactonic:acidic ratio is found with a final ratio of 87:13 after 9 days ( Figure 10). Probably the excess of glucose accumulated because of the limited growth is promoting sophorolipid synthesis.
  • yeast extract concentration is at the standard value of 4 g/L this compound becomes limiting after 48h, resulting in predominantly lactonic forms at early stage of sophorolipid production.
  • the percentage of lactonic forms decreases without going to minority probably due to the supplemental feeding and high excess of oil as was reported by (Davila et al. 1997) ( Figure 10).
  • Citrate has a strong buffering effect and omitting it from the medium results in strong pH decrease with values below 2.5 at the end of exponential phase. As a result of this, cell growth slows down earlier as compared to the reference culture and sophorolipid production is extremely low.
  • the Aat C. bombicola deletion mutant surprisingly behaves comparable to the wild type C. bombicola ATCC22214 regarding the influence of medium composition on the lactonic:acidic ratio of its produced sophorolipids. This creates the opportunity to further direct the production of these new unacetylated sophorolipids to more acidic or more lactonic forms, depending on the needs of a specific application field. It confirms that lactonization is completely independent from acetylation and shows that modification of the lactonization pattern of the new unacetylated sophorolipid mixture is as modifiable as it is for the wild type sophorolipid mixture.
  • An expression construct was created by fusing the C. bombicola AT gene to the constitutive GAPD promotor instead of its native inducable promotor.
  • the GAPD promotor was amplified from plasmid GAPDpromHygro (Van Bogaert et al., 2008a) using the PfuUltra High Fidelity DNA polymerase (Stratagene) and primers GAPDHygro1560 For and GAPDAT FusionB (Table 1).
  • the AT coding region in addition to its terminator sequence were amplified the same way from plasmid pGATtot using primers GAPDAT FusionC and GAPDAT FusionD (Table 1).
  • Both fragments were purified and fused to each other by PCR (Table 4 and 5) : in a first primerless PCR both fragments are allowed to anneal to each other by means of their overlapping sequences and in a second PCR round, the fused product is amplified after adding 0.6mM of each outer primer.
  • the fusion product GAPDATterm was purified from the mix by gelextraction using the Qiaex II gel extraction kit (Qiagen).
  • the 3' downstream sequence of the C. bombicola URA3 locus was coupled to the 3' end of this GAPDATterm fragment. For that, the 3' downstream sequence of the URA3 gene (1450RF3) was amplified from C.
  • the final cassette was cloned in pJET using the CloneJETTM PCR Cloning kit (Fermentas) and the resulting plasmid pJET_AT780overex was transferred to E.
  • the GAPD promotor was amplified using primers GAPDHygro 1560For and GAPDAT FusionBbis and the truncated AT sequence by means of primers GAPDAT FusionCbis and GAPDAT FusionF (Table 1). After purification of both fragments, they were fused by PCR to generate fragment GAPDAT741term. Further generation of the complete overexpression construct AT741overex was done as described for the AT780overex construct.
  • a linear cassette was amplified from plasmid pJET_AT780overex and from pJET_AT741overex using PfuUltra High Fidelity Polymerase and primers ORF4URA3TK bp1 14F and GAPDAT FusionF (Table 1).
  • Cassettes were purified and 140 ng (AT780overex) resp. 126.5 ng (AT741 overex) were used for transformation (1.1.3) of an ura3 deficient C. bombicola derived from wild type C. bombicola ATCC22214.
  • Transformant yeasts were selected on SD medium (1.1.1) and checked by colony PCR for their genotype.
  • sophorolipid yields determined as total peak area in the obtained HPLC- ELSD chromatograms, and the ratio of lactonic to acidic sophorolipids were comparable between both yeast strains. More of interest is the structural variation in terms of acetylation pattern. Under the standard fermentation conditions we have applied here, diacetylated lactonic forms typically are the most predominant compounds produced by C. bombicola. In addition, a significant amount of diacetylated acidic forms are produced while mono- and unacetylated sophorolipids (in both lactonic and acidic configuration) count for minor amounts (Asmer et al., 1988).
  • the three most abundant diacetylated acidic sophorolipids had a molecular mass of 704 (m/z), 706 (m/z) and 708 (m/z) corresponding to sophorolipids with Ci 8: 2, Ci 8: i and Ci 8: o lipid moiety respectively.
  • the relative abundancy of these three peaks was remarkably higher for the AT+780_1 mutant as compared to the wild type yeast ( Figure 13).
  • the C. bombicola acetyltransferase is expressed in a suitable host.
  • This host can either be E. coli or S. cerevisiae.
  • Activity of the acetyltransferase towards alkylglucosides having a decyl aliphatic chain has been shown using the soluble protein fraction of a C. bombicola ATCC22214 cell lysate.
  • Such protein source however contains minor amounts of de novo synthezised sophorolipids that make purification of the acetylated product more complex.
  • a heterologous host unable to produce sophorolipids can simplify the production of acetylated carbohydrate containing compounds in a pure way.
  • a heterologous E. coli BL21 strain harbouring a suitable expression construct has been created. This construct is based on the pTrc99A plasmid (NCCB, The Netherlands) where the acetyltransferase is under control of the strong inducible trc promotor. Induction of protein expression occurs by addition of 0.1 mM IPTG (Carbosynth) to the culture medium, and cells are harvested for lysis 6 hours later.
  • IPTG Carbosynth
  • Enzymatic lysis occurs by means of the EasyLyseTM Bacterial Protein Extraction Solution (Epicentre Biotechnologies) where 200 ⁇ of EasyLyse solution is added to each pellet from a 1 ml culture sample with OD around 4. After lysis, the soluble fraction is used as crude acetyltransferase preparation for subsequent acetylation reactions. These occur in a suitable buffer system and acetylated products can be analysed by HPLC-ELSD after solvent extraction of the reaction mixture. On the other side, a heterologous S. cerevisiae FY 1679-01 B is created using both the pYES2.1 TOPOOTA Expression Kit from Invitrogen and the overexpression constructs created for C. bombicola (see example 2).
  • Cellobioselipids are produced in nature by several fungal species of which the plant pathogenic dimorphic fungus Ustilago maydis is the best known (Hewald et ai, 2006; Spoeckner et ai, 1999). These compounds have attracted attention because of their high antifungal activity (Kulakovskaya et al, 2009 ; Kulakovskaya et ai, 2004 ; Kulakovskaya et ai, 2007). In accordance with sophorolipids, cellobioselipids also occur as mixtures of structurally related molecules where variations occur in acylation pattern and fatty acid composition (Lemieux and Charanduk, 1951).
  • GAPD-775 R colony 5' GCCACTGCCATTGGAGATTG 3' (SEQ ID N° 10)
  • HygrolnsertCh colony 5' TTCGACAGCGTCTCCGACCTGAT 3' (SEQ ID N° 1 1) eck F PCR
  • GAPDHygro15 high 5' GACATCCGATGTGTAGTTAATCA 3' (SEQ ID N° 15) 60
  • SEQ ID N° 15 60
  • Table 4 Composition of the PCR mix for fusion of two fragments. Both fragments are added in a molar ratio of 1 to 1.
  • Fragment 1 max 25 ng/kb x ⁇
  • Fragment 2 max 25 ng/kb x ⁇
  • Hu YM, Ju LK (2001 b) Sophorolipid production from different lipid precursors observed with LC-MS.
  • Van Bogaert INA De Maeseneire SL, Develter D, Soetaert W, Vandamme EJ (2008a) Cloning and characterisation of the glyceraldehyde 3-phosphate dehydrogenase gene of Candida bombicola and use of its promotor. J Ind Microbiol Biotechnol 35 : 1085-1092.
  • Van Bogaert INA Saerens K, De Muynck C, Develter D, Soetaert W, Vandamme EJ (2007) Microbial production and application of sophorolipids. Appl Microbiol Biotechnol 76: 23-34.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Unacetylated sophorolipids show interesting applications in several industrial fields but cannot be produced in a pure and straight way by conventional fermentation. The present invention discloses the production of entirely unacetylated sophorolipids without acetylated variants by fermentation. More specifically, the present invention discloses a yeast strain which is mutated in a gene encoding for an acetyltransferase and which is capable of producing a mixture of entirely unacetylated sophorolipids. Preferably, the majority within said mixture are unacetylated lactonic sophorolipids. In addition, the acetyltransferase of the present invention can be used to acetylate carbohydrates or carbohydrate-containing compounds.

Description

Producing unacetylated sophorolipids by fermentation
Technical field of invention
Unacetylated sophorolipids show interesting applications in several industrial fields but cannot be produced in a pure and straight way by conventional fermentation. The present invention discloses the production of entirely unacetylated sophorolipids without acetylated variants by fermentation. More specifically, the present invention discloses a yeast strain which is mutated in a gene encoding for an acetyltransferase and which is capable of producing a mixture of entirely unacetylated sophorolipids. Preferably, the majority within said mixture are unacetylated lactonic sophorolipids. In addition, the acetyltransferase of the present invention can be used to acetylate carbohydrates or carbohydrate-containing compounds.
Background art
The non-pathogenic yeast Candida (Starmerella) bombicola ATCC 22214 (CBS 6009) is commercially applied for the production of sophorolipids. These glycolipid biosurfactants are constituted of a sophorose head group (2-0^-D-glucopyranosyl-D-glucopyranose) attached to a (sub)terminal hydroxylated Ci8 or Ci6 fatty acid and this by a glycosidic linkage between the anomeric C-atom of the sugar and the hydroxylgroup of the fatty acid. Sophorolipids are typically produced by fermentation in presence of a hydrophobic carbon source and are always constituted of a mixture of structurally related molecules with variation in 1) degree of fatty acid saturation (saturated, mono-unsaturated or di- unsaturated), 2) presence of acetylgroups at C6' and/or C6" atoms, 3) lactonization between the carboxyl end of the fatty acid and either the C4", C6' or C6" atom of the sophorose group, 4) fatty acid chain length and 5) (ω) or (ω-1) hydroxylation of the fatty acid (Asmer ef a/., 1988).
Due to this structural variation, sophorolipids show many interesting applications in a wide range of industrial fields (Banat et al., 2010; Franzetti et al., 2010; Kralova and Sjoblom, 2009; Mulligan, 2009). Since structural composition is reflected in the physico-chemical properties, several industries are particularly interested in specific structural variants. Acetylation is one structural feature that gains a lot of attention especially because of its contribution to biological activity in addition to its influence on water solubility and foaming properties. The decreased cytotoxicity of unacetylated sophorolipids as compared to acetylated variants for example has attracted attention to use these molecules as new antiviral drugs (Shah et al., 2005). On the other hand, the presence of acetylgroups strongly increases antibacterial (Gross and Shah, 2004), antifungal (Gross and Shah, 2005) and antiviral (Shah et al., 2005) properties with diacetylated sophorolipids being better antimicrobial agents as compared to mono-acetylated variants. Furthermore, unacetylated sophorolipids have been used as starting molecules for the synthesis of e.g. dispersible nanoparticles (Kasture et al., 2007) and glycolipid derivatives (Azim et al., 2006; Zerkowski et al., 2006) or have served as source molecules for the production of glucolipids and specialty fatty acids (Rau et al., 2001 ; Saerens et al., 2009), which are on their turn used for synthesis of polymers (Zerkowski et al., 2007) or precursors for plastics and flavours (Rau et ai, 2001).
To date, it is impossible to produce unacetylated sophorolipids in a pure way by fermentation in a concentration of more than 50% of unacetylated sophorolipids within a sophorolipid mixture. The best result obtained so far by fermentation technologies was published by Otto et al. (1999), who obtained a sophorolipid mixture with 45% being unacetylated lactonic forms after a single-step cultivation of C. bombicola ATCC 22214 on whey concentrate and rapeseed oil. The only way to obtain unacetylated sophorolipids in high purity is via the chemical conversion of natural sophorolipid mixtures to unacetylated products by alkaline hydrolysis. By this conversion however, the lactone ring is always hydrolysed and only acidic (= open-ring) unacetylated sophorolipids can be obtained. Since lactonic sophorolipids generally are considered to be industrially more relevant (Hu and Lu, 2001a), a technology that leads to unacetylated sophorolipids herewith leaving the lactone ring intact especially attracts attention.
An alternative way to obtain entirely unacetylated variants would be to prevent acetylation within the sophorolipid-producing organism, e.g. through mutations in or deletions of their acetylating enzymes. Several fungal genomes contain multiple (putative) O- acetyltransferase genes and the specific activity of an O-acetyltransferase is hard to predict based on the amino acid sequence, resulting in a lot of these sequences only being marked as "putative" O-acetyltransferase without any information on the specific action. For instance, in the genome of C. guilliermondii ATCC 6260, 2 putative O- acetyltransferase genes with activity towards sugars can be found. In the genome of Debaryomyces hansenii CBS767, 5 O-acetyltransferases genes can be retrieved with 2 of them possibly involved in sugar acetylation (DEHA2D01 166g, DEHA2F02970g). In the genome of Yarrowia lipolytica CLIB122 these numbers are 5 and 3 respectively (YALI0B1 1176g, YALI0A15081 g, YALI0C00187g) and for Aspergillus nidulans FGSC A4, 8 O-acetyltransferase genes can be found with 5 of them being putative acetyltransferases with activity to sugar molecules (AN6393.2, AN6836.2, AN3419.2, AN1402.2, AN8386.2). Summary of the invention
The present invention provides a nucleic acid molecule consisting of the sequence as depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
In addition, the invention provides a polypeptide consisting of the amino acid sequence as depicted by SEQ ID N° 2 and having acetyltransferase activity, or a fragment thereof retaining said acetyltransferase activity, or a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
The invention further provides the use of a nucleic acid molecule as defined above having lost its capability to encode for a functional acetyltransferase, or, the use of a polypeptide as defined above having lost its acetyltransferase activity to produce a mixture comprising entirely unacetylated sophorolipids.
In a further aspect, the present invention provides a the use of a fungal species which is capable of producing sophorolipids to produce a mixture comprising entirely unacetylated sophorolipids wherein said fungal species has at least one mutation in a nucleic acid molecule defined above and wherein said mixture comprises at least 50% of entirely unacetylated sophorolipids. In particular, said nucleic acid molecule is depicted by SEQ ID N° 1 encoding for an acetyltransferase, or is a fragment thereof encoding for a protein retaining said acetyltransferase activity, or is a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
The invention further provides methods of producing a mixture comprising entirely unacetylated sophorolipids, using a nucleic acid molecule as defined above having lost its capability to encode for a functional acetyltransferase, or, the use of a polypeptide as defined above having lost its acetyltransferase activity. In particular, said method comprises the steps of: a) providing a host cell comprising the nucleic acid molecule or polypeptide as defined above, and b) allowing said host cell to produce sophorolipids using standard culturing techniques. Optionally, said sophorolipids can be isolated or purified from the cell culture. Said host cell can be a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
In a preferred embodiment, said entirely unacetylated sophorolipids comprises at least or equal to 70% of lactonic sophorolipids. In a further embodiment, said yeast species is selected from the group consisting of Candida bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellata, Candida sp. NRRL Y-27208, Rhodotorula bogoriensis, Wickerhamiella domericqiae and sophorolipid-producing species of the Starmerella clade. Preferably, said Candida bombicola is the strain Candida (Starmerella) bombicola ATCC 22214.
In a preferred embodiment, said mutation is a deletion and/or insertion and said deletion and/or insertion results in a non-functional polypeptide.
The invention further provides a modified yeast strain belonging to a fungal species capable of producing sophorolipids, characterized in that said fungal strain, compared to an unmodified wild type strain: a) has at least one mutation in a nucleic acid molecule as defined above, and b) produces a mixture of entirely unacetylated sophorolipids comprising at least 50% of entirely unacetylated sophorolipids. In particular, said nucleic acid molecule is depicted by SEQ ID N° 1 encoding for an acetyltransferase, or is a fragment thereof encoding for a protein retaining said acetyltransferase activity, or is a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
The invention further provides for the use of a polypeptide having acetyltransferase activity as defined above to acetylate carbohydrates or carbohydrate-containing compounds. In particular, said polypeptide consists of the amino acid sequence as depicted by SEQ ID N° 2 and has acetyltransferase activity, or is a fragment thereof retaining said acetyltransferase activity, or is a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity. The invention further provides for methods for acetylating carbohydrates or carbohydrate- containing compounds, using a polypeptide having acetyltransferase activity as defined above.
The invention further provides for the use of a modified host strain expressing a polypeptide having acetyltransferase activity as defined above to acetylate carbohydrates or carbohydrate-containing compounds. In particular, said polypeptide consists of the amino acid sequence as depicted by SEQ ID N° 2 and has acetyltransferase activity, or is a fragment thereof retaining said acetyltransferase activity, or is a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity. The invention further provides for methods of acetylating carbohydrates or carbohydrate- containing compounds, using the modified host strain expressing a polypeptide having acetyltransferase activity as defined above. In a particular embodiment, said modified host strain is transformed with an exogenous nucleic acid molecule as defined above or said modified host strain over-expresses an endogenous nucleic acid molecule as defined above. In particular, said nucleic acid molecule is depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
Preferably, said modified host strain is a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
More preferably, said yeast is Candida (Starmerella) bombicola ATCC 22214.
Brief description of figures
Fig. 1 : The major-but not the sole- components of the new sophorolipid mixture of the present invention. Under the fermentation conditions tested here, entirely unacetylated lactonic 17- and 18-O-sophorosyl-octadecenoic acid were the most predominant structures (a,b), in addition to entirely unacetylated lactonic 17-O-sophorosyl- octadecanoic acid (c) and acidic 17-O-sophorosyl-octadecenoic acid (d).
Fig. 2: Sophorolipids typically produced during fermentation are considered to be a mixture of compounds represented by formulas a) acidic form and b) lactonic form.
Fig. 3: Complete sequence of the C. bombicola AT coding sequence (=SEQ ID N° 1) (GenBank accession number HQ670751) and encoded protein (= SEQ ID N° 2). Conserved amino acids of the active site are written in shaded capitals.
Fig. 4: Alignment of the C. bombicola acetyltransferase sequence with five model sequences that define the conserved domain of Lbh_MAT-GAT subfamily proteins. The 30 conserved amino acids from the active site are indicated by arrows. gi|731964 = putative acetyltransferase YJL218W Saccharomyces cerevisiae, gi| 158333766 = putative maltose O-acetyltransferase Acaryochloris marina MBIC 11017, gi|27552460 = putative O-acetyltransferase Physcomitrella patens, gi| 76803978 = putative maltose O- acetyltransferase Vibrio sp. DAT 722, gi|23466264 = thiogalactoside acetyltransferase Bifidobacterium long urn NCC 2705.
Fig. 5: Schematic representation of the C. bombicola wild type AT locus (A), the knock-out construct (B) and the Aat mutant allele after homologous recombination between the genome and the construct (C). All primers used for generation of the knock-out construct and genotype control of the mutants are indicated. Sites of homologous recombination are marked by dotted lines. Coding sequences are indicated by arrows: AT = Acetyltransferase, hygroR = hygromycin B resistance marker.
Fig. 6: Colony forming units for C. bombicola ATCC 22214 (filled circles) and the Aat deletion mutant (filled squares). Rapeseed oil was added after 48 hours of incubation (arrow).
Fig. 7: HPLC-ELSD chromatogram from the culture extract of a C. bombicola Aat deletion mutant, eleven days after addition of rapeseed oil. Wild type sophorolipids usually elute between 25 and 30 minutes. Corresponding molecular masses were obtained after mass spectrometric analysis of the same sample: unacetylated lactonic 17- and 18-0- sophorosyl-octadecenoic acid (m/z = 604), unacetylated lactonic 17-O-sophorosyl- octadecanoic acid (m/z = 606) and acidic 17-O-sophorosyl-octadecenoic acid (m/z = 622).
Fig 8. Optical density (OD) and glucose consumption for the Aat deletion mutant (AT3) and wild type C. bombicola ATCC22214 (WT) cultivated in a 2L Biostat reactor. Additional glucose (30 g/L) was added to the wild type cultivation after 140 hours. Rapeseed oil (approximately 30 g/L) was added stepwise at 28h, 52h and 117h to AT3 and at 46h, 65h and 140h to WT.
Fig 9. Ratio of lactonic to acidic sophorolipids as a function of incubation time for the Aat deletion mutant (AT3) and wild type C. bombicola ATCC22214 (WT). Total peak area of acidic and lactonic sophorolipids were calculated from HPLC-ELSD chromatograms and expressed relatively to the total peak area of the sample. Cultivation of the AT3 mutant was prolonged to 383h after additional feeding of glucose and rapeseed oil at 309h.
Fig 10. Ratio of lactonic to acidic sophorolipids in the sophorolipid mixture of the Aat deletion mutant AT3 as a function of incubation time and medium composition. Panel A: "Reference" = standard sophorolipid production medium as described by Lang et al. (2000) with 120 g/L glucose, 4 g/L yeast extract, 5 g/L citrate and 40 g/L rapeseed oil; Panel B: "Excess oil" = 50 g/L glucose; Panel C: "YE 15 g/L" = 15 g/L yeast extract; Panel D: "Excess glucose" = 200 g/L glucose; Panel E: ΎΕ 1 g/L" = 1 g/L yeast extract; Panel F: "No citrate" = 0 g/L Na.citrate.2H20.
Fig 11. AT overexpression construct (A), mutant Aura3 locus of the i/ra3-negative C. bombicola (B) and resulting genotype of the AT overexpressing mutant after homologous recombination and double cross-over between the mutated ura3 locus and the construct (C). Primer sites are indicated and regions used for homologous recombination are highlighted by dotted lines. Fig 12. Growth (CFU) and glucose consumption for the AT-overexpressing C. bombicola (AT+78CM) and C. bombicola ATCC2214 (WT) cultivated in a 2L Biostat reactor.
Fig 13. Mass abundance of diacetylated acidic sophorolipids for the AT-overexpressing C. bombicola (AT+78CM) and C. bombicola ATCC2214 (WT) as a function of incubation time. Mass abundances of compounds with molecular masses 704 (m/z), 706 (m/z) and 708 (m/z) were summed and resulting abundances expressed relatively to the total abundance calculated from the total ion chromatogram.
Description of the invention
The present invention discloses the identification of a single acetyltransferase gene AT from Candida (Starmerella) bombicola which is fully responsible for the acetylation of sophorolipids. Deletion of the gene surprisingly results in a yeast species producing only unacetylated sophorolipids (see Figure 1). Moreover, under the standard fermentation conditions the lactonic unacetylated sophorolipids are the predominant molecules in the mutant mixture (see Figure 1). Wth this new structural composition, the created mutant offers a one-step production technology for the fermentative synthesis of industrially important molecules making use of cheap, renewable substrates. Up to date, it was not possible to produce a sophorolipid mixture with this structural composition. Due to the higher foaming capacity and better water solubility of the mutant mixture in addition to the decreased cytotoxicity generally ascribed to unacetylated sophorolipids, these compounds have unique properties and show better performances for several applications such as use as detergent, pharmaceutical applications, cosmetic applications, etc. It should be pointed-out that during the research leading to the present invention two other putative acetyltransferases that belong to the same subfamily as the AT gene, were detected in the genome of C. bombicola. These respectively showed 43% and 38% sequence identity with the AT sequence. Therefore it was not unlikely to think that one of these could replace the AT gene function or that the acetylation is carried out by several independent enzymes (e.g. one takes care of the 6' position, and another of the 6" position). Surprisingly, when creating a single knock-out of the AT gene described in this invention, acetylation of sophorolipid molecules was completely blocked.
In addition, the identification of the AT gene as the single gene responsible for acetylation of sophorolipids, enables the creation of an overexpression mutant where diacetylated sophorolipids are remarkably enriched thus with the mutant mixture being deprived from mono- and unacetylated sophorolipids. Because the significant increase in antibacterial (Gross and Shah, 2004), antifungal (Gross and Shah, 2005) and antiviral (Shah et a/., 2005) activity of diacetylated sophorolipids as compared to mono- or unacetylated variants, such mutant mixture attracts attention of pharmaceutical and medical industries.
The present invention thus relates to the usage of a fungal species which is capable of producing sophorolipids to produce a mixture of entirely unacetylated sophorolipids wherein said fungal species has at least one mutation in a nucleic acid molecule of the present invention encoding for an acetyltransferase of the present invention and wherein said mixture comprises at least 50% of unacetylated sophorolipids. The present invention further preferably relates to the usage as indicated above wherein the majority (i.e. more or equal than 70%) within said mixture are lactonic, unacetylated sophorolipids.
The term 'fungal species capable of producing sophorolipids' refers to a phylogenetically diverse group of yeasts (predominantly Ascomycetes and few Basidiomycetes) which spontaneously synthesize sophorolipids constituted of the sugar sophorose attached to a hydroxylated fatty acid (see Figure 2). Said phylogenetically diverse group of yeasts comprises the species Candida apicola (Gorin et al., 1961) which was initially identified as C. magnolia, C. bombicola (Spencer et al., 1970), Wickerhamiella domericqiae (Chen et al., 2006), Rhodotorula bogoriensis (Tulloch et al., 1968), Candida batistae (Konishi et al., 2008), Candida floricola (Imura et al., 2010), Candida riodocensis, Candida stellata and Candida sp. NRRL Y-27208 (Kurzman et al., 2010) and other species of the so-called Starmerella clade which encompasses over 40 species.
The term 'wherein said fungal species has at least one mutation in a nucleic acid molecule of the present invention encoding for an acetyltransferase of the present invention' refers to a modified yeast species or yeast strain characterized in having at least one mutation in a nucleic acid molecule of the present invention encoding for an acetyltransferase of the present invention. The term 'mutation' refers to a spontaneous mutation and/or to an induced mutation in the genome of said yeast strain. Said mutation can be a point mutation, deletion, insertion or any other type of mutation. The term most specifically refers to knock outs (KO) via insertion of a KO cassette. Inducing a mutation in the genome of a yeast strain can be undertaken by any method in the art known by a skilled person such as the insertion of a KO cassette into a gene of interest. Similarly, tracing or detecting whether there is a mutation in the genome of a modified strain -compared to a wild type strain- can also be done by any method known in the art.
The term 'sophorolipids' (see Figure 2) refers to carbohydrate-based, amphiphilic biosurfactants that are constituted of the sugar sophorose attached to a hydroxylated fatty acid/alkyl chain, i.e. hydroxylated fatty acid/alkyl chains wherein the fatty acid/alkyl chain contains 5 to 26 carbon atoms. Preferably -and especially with regard to C. bombicola- said fatty acid chain is composed of 16 or 18 C-atoms. More specifically the term refers to glycolipid biosurfactants that are constituted of a sophorose head group (2-Ο-β-ϋ- glucopyranosyl^-D-glucopyranose) from which the anomeric C-atom is attached to an (ω) or (ω-1) hydroxylated C10, C12, CM, Ci6, Ci8, C22 or C24 fatty acid. They occur either as open-ring structures (acidic form) or as lactones (closed-ring structures or lactonic form or lactonised form) with an intra-esterification between the fatty acid carboxyl group and the 4", 6' or 6" carbon atom of the sophorose head group. In addition, acetyl groups can be attached at the 6' and/or 6" positions (Asmer et al., 1988).
The term 'unacetylated sophorolipids' refers to sophorolipids without acetylgroups at the C6' and C6" atoms.
The term 'a mixture comprising at least 50% of unacetylated sophorolipids' refers to a mixture which is less complex (as shown in Figure 1) as compared to the mixture which one obtains in a typical wild type Candida bombicola fermentation (Asmer et al., 1988). Indeed the mixture of the present invention is deprived from acetylated forms. In other words, no acetylated forms can be detected -using well-known methods- in the mixture of the present invention.
Hence, the mixture of the present invention comprises at least 50%, i.e. 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100% of unacetylated sophorolipids. Preferably, said mixture of the present invention comprises -or can consist of- a majority of unacetylated lactonic sophorolipids (i.e. more or equal than 70%) and a minority of unacetylated acidic sophorolipids (less than 30%). This lactonic:acidic ratio of unacetylated sophorolipids (i.e. 70%/30%, 71 %/29%, 72%/28%, 73%/27%, 74%/26%, 75%/25%, 76%/24%, 77%/23%, 78%/22%, 79%/21 %, 80%/20%, 81 %/19%, 82%/18%, 83%/17%, 84%/16%, 85%/15%, 86%/14%, 87%/13%, 88%/12%, 89%/11 %, 90%/10%, 91 %/9%, 92%/8%, 93%/7%, 94%/6%, 95%/5%, 96%/4%, 97%/3%, 98%/2%, 99%/1 % or 100%/0%) is surprisingly high and can be influenced by changing the incubation time or the medium composition. . In a typical C. bombicola fermentation on glucose and oleic acid , 62% is composed of diacetylated lactonic forms, 4% is composed of monoacetylated lactonic forms and 4% is composed of unacetylated lactonic forms while the other compounds are constituted of 1 ',6' lactones and 1',6" lactones (4%), acidic sophorolipids (8%) and other lipids at the end of the cultivation period (Asmer et al., 1988). Hu and Ju (2001 b) observed a maximum relative percentage of lactonic forms of 50% using soybean oil and 80% using hexadecane. In another certain experiment where palm esters were used, 79.1 % occurred in the lactonic form, but when sunflower oil was applied, only 55.6 % lactonic sophorolipids were retrieved (Davila et al., 1994). When in a mixed carbon source fed- batch fermentation only oil was added in stationary phase, 13% of sophorolipids were in lactonic form (87% acidic) but when a mixture of oil and glucose was fed in stationary phase, 65% were in lactonic form (Davila et a/., 1997). Yeast extract concentration and presence of citric acid influence the ratio of lactonic to acidic sophorolipids too: when yeast extract concentration was 1 g/L, 65% of sophorolipids were in lactonic forms but when the concentration was increased to 20 g/L, all sophorolipids were in acidic form (Casas and Garcia-Ochoa, 1999). Addition of 5 g/L of citric acid to the medium increased the percentage of lactonic forms in the sophorolipid mixture of Candida apicola (Hommel et al., 1994).
The exact ratio of lactonic to acidic sophorolipids further changes during cultivation with typically more lactonic forms after prolonged incubation times (Casas and Garcia-Ochoa, 1999; Hu and Ju, 2001 b). Hence, the present invention further specifically and preferably relates to the usage as described above wherein said mixture comprises at least or equal to 70% of lactonic, unacetylated sophorolipids.
Furthermore, the present invention relates to the usages as described above wherein said yeast species is selected from the group consisting of Candida bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellata, Candida sp. NRRL Y-27208, Rhodotorula bogoriensis, Wickerhamiella domericqiae and sophorolipid-producing species of the Starmerella clade.
More specifically, the present invention relates to the usage as described above, wherein said Candida bombicola is the strain Candida bombicola ATCC 22214 (CBS 6009).
The present invention also relates to a modified fungal strain belonging to a fungal species capable of producing sophorolipids as described above, characterized in that said fungal strain, compared to an unmodified wild type strain : a) has at least one mutation in the gene encoding for the acetyltransferase of the present invention , and b) produces a mixture comprising at least 50% entirely unacetylated sophorolipids.
The present invention relates to the usages as described above, wherein said mutation is a deletion in the acetyltransferase of the present invention..
The present invention thus relates to a nucleic acid sequence as depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity. SEQ ID N° 1 corresponds to the following open reading frame of 780 base pairs:
1 atggttgtaa actcctcgaa ggaccctcaa aacaaaggaa tgactcctag aaaagaaatt 61 gaccaggaaa tggtctcttg ggccaaaaaa aacctcaaaa acacccctgg caatgaaaac 121 tatgagaaga tggtctcagg agttccttac aatccatacg atccagatct tatgtttaga
181 gccctggcta ctagtgagaa agttagggag ttcaatacca ttgcaagtga aagtcgtact
241 tttgagtcaa atcacgctgc ttatatcaag aaggtcgaga ttctcaaaga cacttttggt
301 caaacaaagg atattgtctg gctgaccgct ccattctcag ttgattttgg attcaacatc
361 agcgtaggcg agcactttta cgccaacttc aacgtttgct tcttggactc ggctccaata
421 atctttggtg atgaggtgat tgtagggccc aatacaacgt tcgtgactgc gactcatcct
481 attagccccg agaaacgtgc gaggagaatt gtgtatgctc ttcctatcaa ggtggggaat
541 aatgtatgga ttggtgcgaa tgtgactgtc ctgccgggtg ttacgattgg agatggctca
601 acaattgcgg ctggtgctgt cgttcgagaa gatgttcctc ctcgtactgt ggtgggagga
661 gtccctgcgc gaatcctcaa gcatattcca gaggaggatc ccgacgaggc tgaaggagag
721 gaactggaat tccttcttcc agttgaaatg aacgtcaata ccgctaacca gaaggtctag
The term 'nucleic acid' and a 'fragment' or a 'variant' thereof corresponds for example to DNA, cDNA, RNA, sense and anti-sense nucleic acids and the like.
The term 'fragment' specifically refers to a nucleic acid sequence containing fewer nucleotides than the nucleic acid sequence as depicted by SEQ ID N° 1 and that encodes for a protein retaining said acetyltransferase activity. The term "variant" specifically refers to a nucleic acid encoding for a protein having at least 50 % sequence identity, preferably having at least 51-70 % sequence identity, more preferably having at least 71-90% sequence identity or most preferably having at least 91 , 92, 93, 94, 95, 96, 97, 98 or 99 % sequence identity with SEQ ID N° 2 (see further) or with a fragment thereof, and, that encodes for a protein retaining said acetyltransferase activity. A specific, but non-limiting example of a fragment of the present invention is a fragment that encodes for the amino acid sequence having SEQ ID N° 13 which corresponds to the following sequence:
1 mtprkeidqe mvswakknlk ntpgnenyek mvsgvpynpy dpdlmfrala tsekvrefnt 61 iasesrtfes nhaayikkve ilkdtfgqtk divwltapfs vdfgfnisvg ehfyanfnvc 121 fldsapiifg devivgpntt fvtathpisp ekrarrivya lpikvgnnvw iganvtvlpg 181 vtigdgstia aga vredvp prt vggvpa rilkhipeed pdeaegeele fllpvemnvn 241 tanqkv
A specific, but non-limiting example of a fragment of the present invention encoding the amino acid sequence having SEQ ID N°13 is the following nucleic acid sequence (SEQ ID N°14): 1 atgactccta gaaaagaaat tgaccaggaa atggtctctt gggccaaaaa aaacctcaaa
61 aacacccctg gcaatgaaaa ctatgagaag atggtctcag gagttcctta caatccatac
121 gatccagatc ttatgtttag agccctggct actagtgaga aagttaggga gttcaatacc
181 attgcaagtg aaagtcgtac ttttgagtca aatcacgctg cttatatcaa gaaggtcgag
241 attctcaaag acacttttgg tcaaacaaag gatattgtct ggctgaccgc tccattctca
301 gttgattttg gattcaacat cagcgtaggc gagcactttt acgccaactt caacgtttgc
361 ttcttggact cggctccaat aatctttggt gatgaggtga ttgtagggcc caatacaacg
421 ttcgtgactg cgactcatcc tattagcccc gagaaacgtg cgaggagaat tgtgtatgct
481 cttcctatca aggtggggaa taatgtatgg attggtgcga atgtgactgt cctgccgggt
541 gttacgattg gagatggctc aacaattgcg gctggtgctg tcgttcgaga agatgttcct
601 cctcgtactg tggtgggagg agtccctgcg cgaatcctca agcatattcc agaggaggat
661 cccgacgagg ctgaaggaga ggaactggaa ttccttcttc cagttgaaat gaacgtcaat
721 accgctaacc agaaggtcta g The present invention further relates to an amino acid sequence as depicted by SEQ ID N° 2 having acetyltransferase activity, or a fragment thereof retaining said acetyltransferase activity or a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
SEQ ID N° 2 corresponds to the following 259 amino acids (given by the one-letter code of amino acids):
1 m vnsskdpq nkgmtprkei dqemvswakk nlkntpgnen yekmvsgvpy npydpdlmfr
61 alatsekvre fntiasesrt fesnhaayik kveilkdtfg qtkdivwlta pfsvdfgfni
121 svgehfyanf nvcfldsapi ifgdevivgp nttfvtathp ispekrarri vyalpikvgn 181 nvwiganvtv lpgvtigdgs tiaaga vre dvpprt vgg vparilkhip eedpdeaege
241 elefllpvem nvntanqkv
The term 'fragment' refers to a protein (or peptide or polypeptide) containing fewer amino acids than the amino acid sequence as depicted by SEQ ID N° 2 and that retains said acetyltransferase activity. Such fragment can -for example- be a protein with a deletion of 10% or less of the total number of amino acids at the C- and/or N-terminus. A specific example is indicated by SEQ ID N° 13. The term "variant" refers to a protein having at least 50 % sequence identity, preferably having at least 51-70 % sequence identity, more preferably having at least 71-90% sequence identity or most preferably having at least 91 , 92, 93, 94, 95, 96, 97, 98 or 99 % sequence identity with SEQ ID N° 2 or with a fragment thereof, and, that encodes for a protein retaining said acetyltransferase activity.
Hence, orthologues, or genes in other genera and species (than the strain Candida bombicola ATCC 22214 from which SEQ ID N° 1 and 2 are derived; with at least 50% identity at amino acid level, and having the described function are part of the present invention. The percentage of amino acid sequence identity is determined by alignment of the two sequences and identification of the number of positions with identical amino acids divided by the number of amino acids in the shorter of the sequences x 100. The latter 'variant' may also differ from the protein as depicted by SEQ ID N° 2 only in conservative substitutions and/or modifications, such that the ability of the protein to have acetyltransferase activity is retained. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of protein chemistry would expect the nature of the protein to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
Variants may also (or alternatively) be proteins as described herein modified by, for example, the deletion or addition of amino acids that have minimal influence on the acetyltransferase activity as defined above, secondary structure and hydropathic nature of the enzyme.
The present invention further relates to the usage of a nucleic acid molecule as defined above having lost its capability to encode for a functional acetyltransferase, or, to the usage of a polypeptide as defined above having lost its acetyltransferase activity to produce a mixture comprising entirely unacetylated sophorolipids. A nucleic acid molecule having lost its capability to encode for a functional acetyltransferase as defined above can be obtained by mutation or by any known means to silence the transcription or translation of said nucleic acid such as the insertion of a nucleic acid fragment, a marker gene or others in the functional coding or non-coding part of the acetyltransferase gene, a mutation or removal of the functional coding or non-coding part of the acetyltransferase gene, the usage of specific siRNAs, miRNAs, combinations hereof or any other way. Similarly, a polypeptide as defined above having lost its acetyltransferase activity can be obtained by any (small) compound or other means to disrupt the function of the acetyltransferases of the present invention. Means to silence the transcription or translation or means to disrupt the function of the acetyltransferase of the present invention or means to disrupt the function of a necessary regulator/activator protein of the acetyltransferase thus comprise the usage of any molecule such as -but not limited to- an antibody, an amino acid, a peptide, a small molecule, an aptamer, a ribozyme, an oligoribonucleotide sequence such a dsRNA used to initiate RNA interference (RNAi) or an anti-sense nucleic acid. Such a molecule is thus capable to bind on a acetyltransferase protein or an activator/regulator protein thereof or is capable to interfere with the cellular synthesis of acetyltransferase or of an activator/regulator thereof by -for example- binding and degrading mRNA's encoding for an acetyltransferase protein or an activator/regulator thereof.
The present invention further relates to the usage of the proteins/polypeptides/peptides having acetyltransferase activity as described above to acetylate carbohydrates or carbohydrate-containing compounds such as sophorolipids, cellobioselipids, alkylglucosides, etc..
Hence, the present invention relates to the usage of a modified host strain expressing a protein having acetyltransferase activity as described above to acetylate carbohydrates or carbohydrate-containing compounds. In this regard, the present invention relates to the usage as described above wherein said modified host strain is transformed with an exogenous nucleic acid sequence as described above or wherein said modified host strain over-expresses an endogenous nucleic acid sequence as described above. As such the present invention relates to the usage as described above, wherein said modified host strain is a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
The present invention and the above-indicated usages will be illustrated by the following non-limiting examples.
Examples
Example 1 : Production of unacetylated sophorolipids
1.1 Materials and Methods
1.1.1 Strains and culture media
C. bombicola ATCC 22214 (CBS 6009) was maintained on YPD medium containing 1 % yeast extract, 2% peptone, 2% dextrose and 2% agarose and incubated at 30°C. For production of sophorolipids, C. bombicola was shifted to 3C medium containing 10% glucose, 1 % yeast extract, 0.1 % urea and 2% agarose before inoculation to liquid production medium described by Lang et al. (2000). Liquid media were incubated at 30°C and 200 rpm for two days before addition of rapeseed oil (37.5 g/L). Escherichia coli DH5oc F' was used for plasmid maintenance and grown on Luria Bertani medium (0.5% Bacto yeast extract, 1 % Bacto Trypton, 0.5% NaCI) containing 0.01 % ampicillin and incubated at 37°C and 200 rpm. Plasmids were isolated by means of the MiniPrep Plasmid Isolation kit from Qiagen and sequenced at AGOWA (Germany).
1.1.2 Creation of the A T knock-out construct
Primer design, sequence analysis and strategy design were performed with the Clone Manager Professional Suite software (Version 8.0). Genome sequencing experiments yielded the pGEM-T® (Promega) derived plasmid pGATtot harbouring the complete acetyltransferase encoding gene sequence in addition to 43 bp and 2426 bp of its up- and downstream sequences respectively. A suitable knock-out construct was created from this plasmid by mutation of the AT gene followed by integration of a selectable marker (hygromycin B). A frameshift was induced in the AT gene by digesting plasmid pGATtot overnight with the single cutter So/I I (New England Biolabs) according to Sambrook (Sambrook and Russell, 2001) resulting in linearization after bp 169 of the AT gene. The linearized plasmid was purified by means of the QIAquick® PCR purification kit from Qiagen and 1.77 μg was subjected to 2U Mung Bean Exonuclease (New England Biolabs) to remove the 5' overhangs. Incubation occured at 30°C for 30 minutes. After purification, 100 ng of the linearized plasmid was self-circularized by overnight incubation at 22°C with 5U T4 DNA ligase (Fermentas) in presence of 5% PEG4000 in T4 DNA ligase buffer (Fermentas). The resulting plasmid was called pGATtot mutAT since it contained a mutated acetyltransferase gene and used for transformation of E. coli DH5aF' according to Sambrook (Sambrook and Russell, 2001). Plasmids of 10 randomly selected transformants were prepared and deletion of the So/I I restriction site was checked by double digestion with Sg/ll and Nco\. The deletion in the AT gene on two positive plasmids was further confirmed by sequencing. Plasmid 10, referred to as pGATtot mutATI O, was chosen for further consideration.
For integration of the hygromycin resistance marker into pGATtot mutATIO, the In-Fusion Dry Down PCR cloning kit (Clontech) was used. Linearisation of pGATtot mutATI O occurred by PCR with PfuUltra High Fidelity DNA polymerase (Stratagene) and primers KOATmutlOlinear inf F and KOATmutIO linear inf R (Table 1). Both primers anneal at the end of the mutated AT gene. A plasmid containing the hygromycin resistance marker in between tyrosine kinase (TK) terminator and C. bombicola GAPD promoter (Van Bogaert et al., 2008a) was used for amplification of the marker by means of primers KOATgapdhygro inf F and KOATgapdhygro inf R (Table 1). These primers each contain 15 bp of homology to the ends of the linearized plasmid pGATtot mutAT allowing subsequent fusion of both fragments. The fusion product was called pGKOAT and cloned in E. Coli Fusion Blue competent cells (Invitrogen), insertion of the marker was verified by colony PCR and correct transformants were used for plasmid isolation as described above. Correctness of the insert was confirmed by sequencing.
1.1.3 Creation of a Aat deletion mutant
A linear knock-out cassette was created from plasmid pGKOAT by PfuUltra High Fidelity DNA polymerase (Stratagene) making use of primers KOAT F and KOAT R (Table 1), the obtained 3742 bp fragment was purified by means of the QIAquick® PCR purification kit (Qiagen) and 688 ng was used for transformation of C. bombicola ATCC 22214 by electroporation. For that, the yeast was grown overnight in 100 ml YPD and when OD reached 1 , cells were harvested from 50 ml by centrifugation during 5 min at 4°C and 200 rpm. After washing twice with cold and sterile mQ water, cells were resuspended in 2 ml sterile sorbitol solution (1 M). After centrifugation at 4°C and 4000 rpm, cells were resuspended in 2 ml sterile lithiumacetate (0.1 M) in presence of 2.5 mM DTT and left to rest at room temperature for 10 to 15 min. Cells were then pelleted again and washed with 2 ml sorbitol (1 M) before resuspending in 250 μΙ sorbitol (1 M). From this suspension, 50 μΙ was carried over into a sterile eppendorf tube, 688 ng of the linear knock-out construct was added and the mixture was incubated on ice for 2 min before transfer to a 2 mm electroporation cuvette. A pulse of 1.5 kV (200 Ohm) was given during 5 milliseconds after which 1 ml of cold and sterile YPD was added immediately. The cells were incubated for 1 h at 30°C and 200 rpm and centrifuged at room temperature during 5 min at 4000 rpm. Cell pellet was then resuspended in 1 ml sorbitol (1 M) and aliquots of 200 μΙ were plated on selective YPD plates containing 500 μg/L hygromycin B. Plates were incubated at 30°C until transformant colonies appeared.
1.1.4 Characterisation of the Aat deletion mutant
The genotype of obtained mutants was checked by means of two yeast colony PCR reactions checking left- and right-sided homologous recombination with primer pairs KOATCtrl F/GAPD -775R and HygrolnsertCheck F/KOATCtrl R respectively (Table 1). The reaction mix was composed of 1.25 U Standard Taq polymerase, 2.5 μΙ reaction buffer and 200 μΜ dNTP's (all from New England Biolabs) in addition to 400 μΜ of each primer and milliQ water to a total volume of 25 μΙ. A single colony was picked by means of a sterile needle and added to the reaction mixture. PCR cycling program was set at 94°C for 7 minutes followed by 30 cycli of subsequently 94°C for 30 s, 54°C for 30 s and 72°C for 2.5 min, the latter having time increments of 5 s per cycle. Final elongation was performed at 72°C during 7 minutes.
The mutants were checked for sophorolipid production by growing them in Lang medium as described above. C. bombicola ATCC 22214 served as a reference. Colony forming units and pH of the cultures were followed at regular time intervals throughout the whole experiment. In accordance, glucose concentrations were determined in the supernatant of 1 ml culture samples by means of HPLC-RI. Sophorolipid formation was checked 1 1 days after addition of rapeseed oil by means of HPLC-ELSD.
1.1.5 Sophorolipid extraction
To determine sophorolipid yields, both C. bombicola ATCC 22214 (wild type) and Aat mutant were grown in 50 ml Lang medium. During incubation of the cultures, sophorolipid production was followed by extracting 1 ml culture sample with 400 μΙ technical ethylacetate in presence of 10 μΙ acetic acid. After vortexing for 5 min and centrifugation at 9000 g for 5 min, 300 μΙ of the solvent phase was diluted in 1.7 ml absolute ethanol and analysed on HPLC-ELSD. Quantitative sophorolipid yields were obtained 19 days after addition of rapeseed oil by addition of 500 μΙ acetic acid to each 50 ml culture and extracting three times with one volume of technical ethylacetate. Solvent phases were poured together and evaporated to dryness. Residual oil was removed and quantified by washing the crude extract twice with 10 ml technical n-hexane and evaporating combined hexane phases to dryness. Purity of the extracts was checked by means of HPLC-ELSD.
1.1.6 High Performance Liquid Chromatography
Glucose samples were analysed on a Varian ProStart HPLC system equipped with an Aminex® HPX-87H ion exclusion column (300 mm x 7.8 mm) (Biorad) coupled to a LaChrom Rl detector (Merck). Column temperature was at 65°C and compounds were eluted in 25 minutes by means of a 5 mM H2S04 solution at a constant flow rate of 0.6 ml/min. Culture extracts were analysed for sophorolipid content on a Varian ProStar HPLC system equipped with a Chromolith® Performance RP-18e 100-4.6-mm column (Merck KGaA) and connected to an Evaporative Light Scattering Detector (Alltech). Compounds were eluted by means of an acetonitrile/acetic acid (0.5% in water) gradient (5/95 to 95/5 in 40 min) under constant flow of 1 mL/min. Column temperature was set at 30°C. To check molecular masses of the produced sophorolipids, the same samples were analysed under the same conditions on a Shimadzu LC-10-AD HPLC system connected to a quadrupole mass spectrometer (Waters). Molecules were identified by their native molecular masses after ESI (electron spray ionisation) without collision.
1.1.7 Biostat 1 L Fed-Batch fermentation
To study sophorolipid production in more detail, a 1 L fermentation was set up with the C. bombicola Aat mutant AT3 and compared to the wild type yeast ATCC22214. A 100 ml preculture in medium of Lang et al. (2000) was inoculated from a 3C agar plate (1.1.1) and grown overnight at 30°C and 200 rpm. This preculture was used as inoculum for 1 L fresh medium in a 2L benchtop BioStat fermentor (Sartorius Stedim Biotech, Germany). At the time of inoculation, 10% (v/v) sterile rapeseed oil was added to the preculture. Aeration rate was 1 L/min, agitation speed 800 rpm and temperature set at 30°C. pH was allowed to drop freely to 3.5 and was then buffered at this value by means of NaOH (5N). Rapeseed oil was added in fed-batch manner (in a total concentration of 37 g/L for the AT3 mutant and 30 g/L for the wild type yeast) generally in steps of 10 g/L at times were foaming became significant or when no residual oil was observed in daily taken samples. If necessary, also glucose was added in fed-batch manner. At regular time points, samples were taken to follow OD, glucose concentration and sophorolipid production (see 1.1.5 and 1.1.6). Glucose samples were quantified by means of a YSI Select 2700 Biochemistry Analyzer.
1.1.8 Lactonic:Acidic ratio as a function of medium composition
The effect of medium composition on the ratio of lactonic to acidic sophorolipids in the mixture of the AT3 mutant was evaluated in erlenmeyer flask experiments. One preculture of 100 ml production medium was prepared (1.1.1) and used to inoculate six 100 ml cultures with startOD equal to 0.2. All cultures were based on the medium described by Lang et al. (2000), but in 5 of them some slight modifications were incorporated as summarized in Table 3. To all cultures, 40 g/L rapeseed oil was added in 4 steps of 10 g/L after 48h, 96h, 144h and 192h. In the culture "excess glucose" stepwise addition of rapeseed oil was accompanied by additional feeding of 20 g/L glucose. At regular time points, colony forming units, glucose concentration, pH, optical density and sophorolipid production were determined as described above. 1.2 Results
1.2.1 Analysis of the C. bombicola acetyltransferase
Genome sequencing experiments with C. bombicola ATCC 22214 revealed a putative open reading frame of 780 bp with high homology to putative bacterial and fungal carbohydrate transacetylases, as shown by a blastx homology search to all non-redundant protein sequences available at the NCBI database (Altschul et al., 1997). Table 2 gives an overview of the ten best blastx-hits. Highest homology of 65% (47% sequence identity) is found to a putative protein from Clavispora lusitaniae ATCC 42720 (gb/EEQ36094). The putative C. bombicola acetyltransferase of 259 amino acids had an estimated molecular mass of 28.6 kDa and estimated pi of 4.96. The complete coding sequence is given in Figure 3. The complete AT gene was submitted to GenBank under accession number HQ670751.
Analysis of the acetyltransferase (At) protein sequence via the Conserved Domain Database (CDD) (Marchler-Bauer et al., 2009) at the NCBI website, shows that the protein belongs to the LbetaH superfamily (CDD accession number cd00208) of proteins, characterised by a left-handed parallel β-helix. Most of these proteins show acetyltransferase activity though some are involved in iron transport and translation initiation. The presence of a LbH_MAT_GAT conserved domain (CDD accession number cd003357) in the C. bombicola At sequence, confirms that this protein belongs to the Maltose-O-Acetyltransferase (MAT) and Galactoside-O-acetyltransferase (GAT) subfamily of the LbHMATJike protein family (CDD accession number cd 04647). All putative proteins with high homology (Table 2) show this same conserved domain in their sequence. Figure 4 illustrates the alignment of the C. bombicola At protein sequence with five model sequences used to define the conserved domain. Both MAT and GAT catalyze the CoenzymeA-dependent acetylation of the C6 carbon atom of their respective carbohydrates. For MAT however, activity was observed to substrate analogues which have a hydrophobic side chain attached to the carbohydrate molecule. An active acetyltransferase is a trimer with three active sites being formed by the LbH interfaces. Each active site is a coenzyme A binding site, represented by 15 conserved amino acid residues. 1.2.2 Creation of the Aat deletion mutant
To find out whether this gene is involved in sophorolipid production, a deletion mutant was created from C. bombicola ATCC 22214. Recombination efficiency in C. bombicola is increased when double-sided homologous recombination can occur between the targetted genome locus and a linear DNA fragment of which both left- and right-sided flanks show around 1000 bp homology with the genomic sequence (Van Bogaert et al., 2008b). Thus, a suitable knock-out cassette is usually based on the integration of a selectable marker between 1000 bp of the 5' and 3' ends of the gene that needs to be deleted. The creation of the Aat deletion construct was started from plasm id pGATtot, a pGEM-T® derived plasmid harbouring the complete AT coding sequence (780 bp) in addition to 43 bp of the upstream and 2426 bp of the downstream sequences respectively. For that, first a frame- shift was introduced in the AT coding sequence to assure that homologous recombination between wild type AT locus and the construct would result in the replacement of the AT gene by a disfunctional at copy. Figure 5 shows a schematic drawing of the wild type AT locus, the created knock-out construct and the Aat mutant locus after homologous recombination between construct and genome.
After transformation of C. bombicola ATCC 22214 with the knock-out construct, many transformants were observed on the selective YPD plates of which 72 were subjected to yeast colony PCR to check their genotype. Of these, 88% resulted from double cross-over events, 8% from single cross-over events and 4% from illegitimate recombination. From the double cross-over mutants, three yeast colonies were randomly selected for further study of the phenotype.
1.2.3 Sophorolipid production by the Aat deletion mutant
All three mutants showed equal growth as compared to the wild type yeast when grown in Lang medium with addition of rapeseed oil. For one randomly selected mutant, colony forming units were followed during cultivation and compared to the values obtained for the wild type yeast (Figure 6). After 9 days (7 days after addition of rapeseed oil), glucose was completely depleted in both cultures. Sophorolipid production was checked for all three mutants and the wild type yeast eleven days after addition of rapeseed oil, and the HPLC- ELSD chromatograms obtained showed that all three Aat deletion mutants produced identical sophorolipids which were clearly more polar as compared to those from the wild type yeast. To verify if this was due to the absence of acetylation, the culture extract from one randomly selected mutant was analysed by mass-spectrometry. Figure 7 shows the HPLC-ELSD result from a culture extract from the Aat mutant AT4 and the corresponding masses as obtained by mass-spectrometric analysis. These masses confirm that only unacetylated sophorolipids were produced. Entirely unacetylated lactonic 17- and 18-0- sophorosyl-octadecenoic acid (m/z = 604) were the most predominant structures in the mixture, in addition to minor amounts of open-ring 17-O-sophorosyl-octadecenoic acid (m/z = 622) and lactonic 17-O-sophorosyl-octadecanoic acid (m/z = 606). No acetylated variant was observed in the mixture.
To determine total sophorolipid yield, the experiment was repeated and a total extraction was done 19 days after addition of rapeseed oil. While the wild type yeast produced 33 ± 4 g/L sophorolipids, only 5 ± 0.7 g/L were obtained from the mutant. Accordingly, 15.4 ± 0 g/L residual oil was found for the mutant while no residues could be detected for the wild type yeast. By this time, glucose was almost completely consumed by both cultures (0.07 ± 0.03 g/L residual glucose for the wild type and 0.13 ± 0.03 g/L for the mutant). Although the extraction procedure might need some optimization for the new sophorolipid mixture (the culture supernatant still contained minor amounts of sophorolipids), the significant amount of residual oil indicates that conversion of rapeseed oil to unacetylated sophorolipids by the Aat deletion mutant occurs with lower efficiency as compared to native sophorolipid production by the wild type yeast. This might be explained by less efficient export of the unacetylated sophorolipids herewith delaying further synthesis of the compounds. Though the ABC transporter involved in secretion of cellobioselipids by U. maydis appeared not to be very selective (Teichmann et al., 2007), the secretion of mannosylerythritol lipids by the same fungus seemed to require a double acylation at the 2' and 3' carbon of the mannosyl residue (Hewald et al., 2006). Sort of selectivity of a transporter involved in sophorolipid secretion is thus not impossible. However, yields might be increased by optimization of process parameters e.g. fed-batch addition of rapeseed oil instead of batch.
The created Aat deletion mutant produces mainly lactonic unacetylated sophorolipids. These are only produced in very minor amounts during conventional fermentation with C. bombicola or any other sophorolipid producing yeast species. The created mutant thus produces a new and inventive sophorolipid mixture which is mostly constituted of unacetylated lactonic glycolipids. Although sophorolipids are classified as low-foaming detergents, the unacetylated sophorolipid mixture of the mutant clearly showed increased foaming as was observed during extraction from the culture broth. The lack of acetylgroups tremendously increases the water solubility of the product so that the unacetylated sophorolipids have unique properties that are of interest to several industries. Since both acetylation and lactonization have important contributions to the antimicrobial, antiviral and cytotoxic properties, the unacetylated lactonic sophorolipids are of interest to pharmaceutical industry as well (Gross and Shah, 2004; Gross and Shah, 2005, Shah et al., 2005).
1.2.4 Evaluation of sophorolipid production in a BioStat 1 L bioreactor
In order to evaluate growth and sophorolipid production in a more controlled manner the C. bombicola AT3 mutant was cultivated in a BioStat 2L fermentor and compared with the wild type yeast grown under the same conditions. Figure 8 shows the growth curve and glucose consumption for the AT3 mutant as compared to the wild type yeast. In this well- controlled bioreactor experiment, glucose consumption and optical density in the exponential phase is comparable between wild type yeast and AT3 mutant illustrating equal growth rates. In late exponential phase (at the onset of sophorolipid production) and throughout the whole stationary phase however, glucose is clearly faster consumed by the wild type yeast as compared to the AT3 mutant indicating that more glucose is directed to sophorolipid production in the cultivation with the wild type yeast. The steeper increase in optical density, typically related to sophorolipid production in stationary phase, further illustrates that this happens more efficiently in the wild type cultivation as compared to the AT3 cultivation. HPLC-ELSD analysis of the sophorolipids confirmed that total sophorolipid peak area was at the maximum factor 50 higher for the wild type sample extracts as compared to those of the mutant (results not shown). To investigate the structural composition of the sophorolipid mixture produced, and more specifically the ratio of lactonic to acidic sophorolipids, the peaks observed in the HPLC-ELSD chromatograms were first structurally identified after analysis of the same samples on HPLC-MS (1.1.6). Subsequently, the compounds were divided in two main groups: the acidic sophorolipids typically eluting between 19 and 25 min and the lactonic forms typically found between 25.5 and 30.5 min. Peak areas were calculated for both groups and expressed relatively to the total peak area obtained. Figure 9 illustrates the lactonic to acidic ratios in the sophorolipid mixtures of both strains. Generally the most predominant sophorolipids produced under conventional fermentation conditions (excess of glucose and in addition of a hydrophobic carbon source) are lactonic ones, and the ratio of lactonic to acidic sophorolipids further increases upon incubation. As clear from Figure 9, this is not only true for the wild type yeast but also for the AT3 mutant. While the ratio lactonic:acidic is initially a bit lower as compared to the wild type (70:30 as compared to 92:8), the final ratio obtained becomes comparable. Because after 212h there was still glucose present in the culture supernatant of the AT3 mutant, this cultivation was prolonged to 309h and finally to 383h after additional feeding of glucose (46 g/L) and rapeseed oil (10 g/L) after 309h. This prolonged incubation finally yielded a lactonic:acidic ratio of 99.9:0.1. It is surprising that lactonic forms are the most predominant compounds in the mixture of the Aat deletion mutant and the fact that the ratio of lactonic to acidic sophorolipids in the mutant mixture is comparable to the wild type yeast indicates that the defectiveness of the acetylation function does not influence the lactonization pattern of the sophorolipids proving that acetylation is not a prerequisite for lactonization.
1.2.5 Ratio of lactonic to acidic sophorolipids in function of medium composition
Unacetylated sophorolipids are of interest to several industries due to their different biological properties, foaming properties and better water solubility. For some applications, lactonic sophorolipids are preferable above acidic ones while for other industries the opposite might be true. Indeed, lactonization has a strong contribution to the overall polarity and chemical versatility of the sophorolipid. For wild type C. bombicola as well as for C. apicola, many papers have illustrated the effect of medium composition on the amount of acidic and lactonic sophorolipids (Casas and Garcia-Ochoa, 1999; Davila et al., 1992; Davila et al., 1994; Hommel et al., 1994; Hu and Ju, 2001 b). To investigate these effects on the mixture of unacetylated sophorolipids of the Aat deletion mutant and in that way explore the flexibility of the mutant in view of tailored production of unacetylated sophorolipids in each of both configurations, 5 cultures with adapted composition were compared to the standard sophorolipid production medium as described by Lang et al., (2000). The ratio of glucose to oil, the concentration of yeast extract and the presence or absence of citric acid were the investigated parameters. Figure 10 shows the results regarding the sophorolipid lactonic:acidic ratios under the different conditions. The amount of glucose to oil, the concentration of yeast extract as well as the presence of citrate are clearly affecting the sophorolipid composition of the AT3 mutant. Not only sophorolipid lactonic:acidic ratio, but also cell growth is affected by a change in yeast extract concentration or the omittment of citrate. Since yeast extract is rich in growth factors, a decrease in its concentration to 1 g/L results in an early delay of cell growth (and corresponding glucose consumption) as compared to the standard production medium with 4 g/L yeast extract. Surprisingly, sophorolipid production is comparable to the standard conditions indicating higher productivity of the cells and the same lactonic:acidic ratio is found with a final ratio of 87:13 after 9 days (Figure 10). Probably the excess of glucose accumulated because of the limited growth is promoting sophorolipid synthesis. Accordingly, increasing the concentration to 15 g/L results in a prolongation of the growth phase, early glucose depletion and limited sophorolipid production. Total sophorolipid production in this case is comparable to the culture where initial glucose concentration was lower ("Excess oil") but the pattern in lactonic:acid ratio during the incubation period is different (Figure 10). In high yeast extract concentrations (ΎΕ 15 g/L"), acidic sophorolipids are the most predominant compounds formed but from the moment glucose becomes limiting, the relative amount of lactonic sophorolipids increases and the mixture slowly shifts to predominantly lactonic forms after 140h with a final ratio of 65:35 after 9 days. Though the final ratio of the culture with limited initial glucose concentration ("Excess oil") is comparable (57:43 after 9 days, see Figure 10) as is the moment of glucose depletion, the pattern shift in lactonic:acidic ratio of the latter culture is different with predominantly lactonic forms in early stage of sophorolipid production. In contrast to the culture with high yeast extract concentration (YE 15g/L), the importance of lactonic sophorolipids here declines in function of incubation time. This suggests that yeast extract is somehow promoting the synthesis of acidic sophorolipids or limitates the production of lactonic sophorolipids as was also reported by Casas and Garcia-Ochoa (1999). Indeed, under initially high yeast extract concentrations, it takes some time before this compound becomes limiting inducing a late shift to more lactonic forms at the end of the cultivation. When yeast extract concentration is at the standard value of 4 g/L this compound becomes limiting after 48h, resulting in predominantly lactonic forms at early stage of sophorolipid production. The percentage of lactonic forms decreases without going to minority probably due to the supplemental feeding and high excess of oil as was reported by (Davila et al. 1997) (Figure 10). Citrate has a strong buffering effect and omitting it from the medium results in strong pH decrease with values below 2.5 at the end of exponential phase. As a result of this, cell growth slows down earlier as compared to the reference culture and sophorolipid production is extremely low. Under such conditions, acidic sophorolipids are the main compounds produced with a stable lactonic:acid ratio of about 10:90 (Figure 10). It has been reported by Hommel et al. (1994) that presence of citrate induces production of lactonic sophorolipids and it has been suggested that this is due to an activation of the lactonesterase responsible for lactonization of the molecules. However, the fact that the pH drops to extremely low values rises the idea that this pH effect is the direct parameter affecting sophorolipid structure, either by inhibiting an extracellular lactonesterase or by spontaneous cleavage of the ester bounds in the lactonic sophorolipids. Finally, the culture where addition of oil was accompanied by supplemental feeding of glucose ("Excess glucose") results in the same growth characteristics and sophorolipid production as compared to the standard production medium. In this standard medium, glucose is added already in excess and additional feeding of glucose in stationary phase just prevents limitation thereof. The final lactonic:acid ratio is comparable with the reference culture (92:8 for "Excess glucose" culture as compared to 87: 13 for "Reference" culture, Figure 10). It is possible that supplemental addition of glucose keeps the glucose:oil ratio quite high in comparison with the standard production medium where this ratio becomes small under glucose depletion at the end of the cultivation period. In agreement with the report of Davila et al. (1997), this might result in a small relative increase in acidic forms for the reference culture which is not observed for the culture "Excess glucose" though cultivation needs to be followed up for longer incubation times to judge if this difference is significant or not.
To conclude, the Aat C. bombicola deletion mutant surprisingly behaves comparable to the wild type C. bombicola ATCC22214 regarding the influence of medium composition on the lactonic:acidic ratio of its produced sophorolipids. This creates the opportunity to further direct the production of these new unacetylated sophorolipids to more acidic or more lactonic forms, depending on the needs of a specific application field. It confirms that lactonization is completely independent from acetylation and shows that modification of the lactonization pattern of the new unacetylated sophorolipid mixture is as modifiable as it is for the wild type sophorolipid mixture.
Example 2: Production of sophorolipids enriched in diacetylated forms
2.1 Materials and Methods
2.1.1 Creation of the ^T overexpression construct
An expression construct was created by fusing the C. bombicola AT gene to the constitutive GAPD promotor instead of its native inducable promotor. For that the GAPD promotor was amplified from plasmid GAPDpromHygro (Van Bogaert et al., 2008a) using the PfuUltra High Fidelity DNA polymerase (Stratagene) and primers GAPDHygro1560 For and GAPDAT FusionB (Table 1). The AT coding region in addition to its terminator sequence were amplified the same way from plasmid pGATtot using primers GAPDAT FusionC and GAPDAT FusionD (Table 1). Both fragments were purified and fused to each other by PCR (Table 4 and 5) : in a first primerless PCR both fragments are allowed to anneal to each other by means of their overlapping sequences and in a second PCR round, the fused product is amplified after adding 0.6mM of each outer primer. The fusion product GAPDATterm was purified from the mix by gelextraction using the Qiaex II gel extraction kit (Qiagen). The 3' downstream sequence of the C. bombicola URA3 locus was coupled to the 3' end of this GAPDATterm fragment. For that, the 3' downstream sequence of the URA3 gene (1450RF3) was amplified from C. bombicola ATCC 22214 genomic DNA (Saerens et al., 2011) by PfuUltra High Fidelity polymerase using primers GAPDATterm FusionE and GAPDAT FusionF (Table 1). The GAPDATterm fragment was prepared for fusion by amplification with the same polymerase using primers GAPDHygro1560 For and GAPDATterm RevFus (Table 1). After purification, both fragments were fused as described above giving rise to the fragment GAPDATterm_1450RF3. This fragment was purified from the mix by gelextraction. The selection marker URA3 in addition to its 5' upstream sequence (ORF4URA3) was amplified from C. bombicola ATCC 22214 genomic DNA by PfuUltra High Fidelity PCR using primers P1 and URA3TK Rev (Table 1). The TK terminator was amplified from plasmid GAPDpromHygro (Van Bogaert et al., 2008a) using primers URA3TK For and HygroCDS&T Rev (Table 1) and fused to the ORF4URA3 fragment as described above to create the fragment ORF4URA3TK. After gelextraction, the latter fragment was fused to the GAPDATterrrM 450RF3 fragment. For that GAPDATterrrM 450RF3 was amplified by means of primers GAPDAT ForFus short and GAPDAT FusionF while ORF4URA3TK was amplified using primers ORF4URA3TK bp21 F and URA3TK RevFus short. After purification, both fragments were fused to give rise to the final overexpression construct ORF4URA3TK_GAPDATterm1450RF3 (= AT780overex). The final cassette was cloned in pJET using the CloneJET™ PCR Cloning kit (Fermentas) and the resulting plasmid pJET_AT780overex was transferred to E. coli XL10 Gold cells for plasmid maintenance following the protocol of Inoue (Sambrook and Russell, 2001) with addition of 2 μΙ β- mercaptoethanol (Stratagene). The correctness of the sequences on plasmid pJET_AT780overex was checked by sequencing. A second overexpression construct, harbouring part of the AT coding sequence under control of the GAPD promotor was generated the same way. This partial AT sequence lacks the first 39 bp leading to a 5' truncated sequence referred to as AT741. The corresponding fragment GAPDAT741term was generated by PCR using fragment GAPDATterm as a template. The GAPD promotor was amplified using primers GAPDHygro 1560For and GAPDAT FusionBbis and the truncated AT sequence by means of primers GAPDAT FusionCbis and GAPDAT FusionF (Table 1). After purification of both fragments, they were fused by PCR to generate fragment GAPDAT741term. Further generation of the complete overexpression construct AT741overex was done as described for the AT780overex construct.
2.1.2 Creation and characterization of an ΛΓ-overexpressing C. bombicola
A linear cassette was amplified from plasmid pJET_AT780overex and from pJET_AT741overex using PfuUltra High Fidelity Polymerase and primers ORF4URA3TK bp1 14F and GAPDAT FusionF (Table 1). Cassettes were purified and 140 ng (AT780overex) resp. 126.5 ng (AT741 overex) were used for transformation (1.1.3) of an ura3 deficient C. bombicola derived from wild type C. bombicola ATCC22214. Transformant yeasts were selected on SD medium (1.1.1) and checked by colony PCR for their genotype. Left- and right-sided cross-over was checked by primer pairs P33 and URA3Un respectively P35 and ATR (Table 1). Selected mutants arising from a double cross-over event were grown in sophorolipid production medium (1.1.1) to check their phenotype (growth and glucose consumption) and sophorolipid production. Wild type C. bombicola ATCC22214 was taken as a reference. In order to follow up sophorolipid production under well-controlled conditions, one of those mutants was used in a 1 L Fed- Batch fermentation and growth, glucose consumption and sophorolipid production were compared to the wild type yeast (1.1.7). Daily samples were analysed for sophorolipids as described in 1.1.5 and 1.1.6. Final sophorolipid yields were quantified by a total extraction of the fermentation broth. For this, 3 volumes of technical ethanol were added to the fermentation broth and cellular debris was removed by centrifugation at 8000 rpm for 10 min. The supernatant was evaporated to dryness and the residue redissolved in 2.5 volumes technical ethanol before filtration. Non-dissolved particles were additionally rinsed with half a volume of technical ethylacetate to assure complete solubilization of all sophorolipids. The filtrate was evaporated to dryness and rinsed with half a volume of technical hexane. The hexane phase was removed and evaporated to dryness. Sophorolipid yields and residual oil were determined by weighing the residues obtained from the ethanol/ethylacetate and hexane phase respectively.
2.2 Results
Based on homologies between the 5' and 3' ends of the AT-overexpression construct and the mutated ura3 locus of the ura3 deficient host, integration of the /AT-overexpression cassette occurs at this specific locus on the genome, resulting in one additional copy of the AT gene under control of the constitutive GAPD promotor (Figure 11). Indeed, the Ai/ra3-deficient host still harbours its native copy of the AT gene under its own promotor elsewhere in its genome. In this way, acetyltransferase synthesis from this GAPD- controlled gene results in protein during the exponential growth phase of the mutant. This will result in a cytoplasmatic pool of acetyltransferase protein by the time sophorolipid production is initiated by nitrogen limiting conditions at the end of the exponential phase. In that way, more acetylation of freshly synthesised sophorolipids can occur leading to an enrichment of diacetylated forms and deprivation of mono- and unacetylated forms. Several mutants were obtained after transformation of the i/ra3-deficient C. bombicola with the overexpression constructs AT780overex (the complete AT sequence) and AT741overex (the truncated AT sequence). Two mutants that had resulted from a double cross-over event for each construct were subsequently grown in sophorolipid production medium and compared to the wild type C. bombicola ATCC22214. All mutants showed comparable growth, glucose consumption and sophorolipid production as compared to this wild type yeast. In order to investigate the effect of the constitutively expressed AT copy on the structural variation of sophorolipids, one mutant referred to as AT+78CM was grown in a 2L bioreactor and compared to the wild type yeast. Figure 12 shows the growth and glucose consumption for the AT overexpressing mutant AT+78CM as compared to wild type C. bombicola ATCC22214. From this figure it is clear that the AT overexpressing mutant shows equal growth characteristics as compared to the wild type yeast. Also sophorolipid yields, determined as total peak area in the obtained HPLC- ELSD chromatograms, and the ratio of lactonic to acidic sophorolipids were comparable between both yeast strains. More of interest is the structural variation in terms of acetylation pattern. Under the standard fermentation conditions we have applied here, diacetylated lactonic forms typically are the most predominant compounds produced by C. bombicola. In addition, a significant amount of diacetylated acidic forms are produced while mono- and unacetylated sophorolipids (in both lactonic and acidic configuration) count for minor amounts (Asmer et al., 1988). The additional AT copy in the genome of the mutant AT+78CM is under control of the GAPD promotor and will thus lead to synthesis of acetyltransferase during the exponential growth phase. As a result of this, there will be a pool of acetyltransferase protein by the time that sophorolipid production is initiated at early stationary phase leading to more efficient acetylation of the freshly synthesized compounds and ideally bringing the number of mono- and unacetylated sophorolipids to zero. In all the samples we prepared from both wild type and AT overexpressing yeast, diacetylated lactonic sophorolipids were as expected the most important structural variants in addition to significant amounts of diacetylated acidic forms. To investigate the effect of the additional AT copy on the acetylation pattern of the sophorolipids, the relative abundancy of the diacetylated acidic sophorolipids was calculated from the mass spectra obtained. Indeed, the pool of acetyltransferase present in the AT+780_1 mutant at the onset of sophorolipid production will lead to more efficient acetylation at this early stage of production which is characterised by a higher relative amount of acidic forms as compared to later stages of production. The three most abundant diacetylated acidic sophorolipids had a molecular mass of 704 (m/z), 706 (m/z) and 708 (m/z) corresponding to sophorolipids with Ci8:2, Ci8:i and Ci8:o lipid moiety respectively. In all samples obtained during the whole cultivation period, the relative abundancy of these three peaks was remarkably higher for the AT+780_1 mutant as compared to the wild type yeast (Figure 13). These results demonstrate that under standard fermentation conditions, one additional copy of the AT gene under control of the constitutive GAPD promotor results in a remarkable increase in diacetylated acidic sophorolipids as compared to the wild type C. bombicola ATCC22214 and this counts for the whole incubation period.
Example 3: Acetylation of other carbohydrate containing compounds
For acetylation of other glucopyranose containing glycolipids such as cellobioselipids or glucolipids, or alkylglucosides the C. bombicola acetyltransferase is expressed in a suitable host. This host can either be E. coli or S. cerevisiae. Activity of the acetyltransferase towards alkylglucosides having a decyl aliphatic chain has been shown using the soluble protein fraction of a C. bombicola ATCC22214 cell lysate. Such protein source however contains minor amounts of de novo synthezised sophorolipids that make purification of the acetylated product more complex. For that, a heterologous host unable to produce sophorolipids can simplify the production of acetylated carbohydrate containing compounds in a pure way. A heterologous E. coli BL21 strain harbouring a suitable expression construct has been created. This construct is based on the pTrc99A plasmid (NCCB, The Netherlands) where the acetyltransferase is under control of the strong inducible trc promotor. Induction of protein expression occurs by addition of 0.1 mM IPTG (Carbosynth) to the culture medium, and cells are harvested for lysis 6 hours later. Enzymatic lysis occurs by means of the EasyLyse™ Bacterial Protein Extraction Solution (Epicentre Biotechnologies) where 200 μΙ of EasyLyse solution is added to each pellet from a 1 ml culture sample with OD around 4. After lysis, the soluble fraction is used as crude acetyltransferase preparation for subsequent acetylation reactions. These occur in a suitable buffer system and acetylated products can be analysed by HPLC-ELSD after solvent extraction of the reaction mixture. On the other side, a heterologous S. cerevisiae FY 1679-01 B is created using both the pYES2.1 TOPOOTA Expression Kit from Invitrogen and the overexpression constructs created for C. bombicola (see example 2).
Cellobioselipids are produced in nature by several fungal species of which the plant pathogenic dimorphic fungus Ustilago maydis is the best known (Hewald et ai, 2006; Spoeckner et ai, 1999). These compounds have attracted attention because of their high antifungal activity (Kulakovskaya et al, 2009 ; Kulakovskaya et ai, 2004 ; Kulakovskaya et ai, 2007). In accordance with sophorolipids, cellobioselipids also occur as mixtures of structurally related molecules where variations occur in acylation pattern and fatty acid composition (Lemieux and Charanduk, 1951). Since acetylation has been shown to strongly influence the antifungal spectrum of sophorolipids (Gross and Shah, 2005), this is also expected for cellobioselipids. Therefore, it is interesting to acetylate cellobioselipids with acetylgroups instead of the naturally occuring acylgroups. For this, unacylated cellobioselipids are used as substrate for the above mentioned in vitro acetyltransferase reaction. Natural cellobioselipids are obtained after cultivation of haploid Ustilago maydis DSM17146 (Hewald et al., 2005) on Potato Dextrose Broth (PDB) for one week. After cultivation, total cellobioselipid extraction occurs with ethylacetate and the solvent is removed by evaporation. The cellobioselipids are subsequently converted to the acidic deacylated form by alkaline hydrolysis following the protocol as described for sophorolipids (Saerens et al., 2009). Deacylation of the cellobioselipids was confirmed by mass spectrometry. These deacylated cellobioselipids will be used in an acetyltransferase assay to give rise to acetylated cellobioselipids instead of the natural acylated cellobioselipids. Presence of acetylated cellobioselipids will be verified by solvent extraction of the reaction mixture and subsequent analysis on HPLC-ELSD.
Table 1. Primers used for creation of the Aat knock-out construct, AT overexpression construct and genotype control of the obtained transformants. All primers were ordered at Sigma Genosys.
Primer name Primer Sequence
function
KOATmutlOlin linearisatio 5' GGATCCTCCTCTGGAATATG 3' (SEQ ID N° 3) ear inf F n pGATtot
mutAT
KOATmutlOlin linearisatio 5' CGAGGCTGAAGGAGAGGAAC 3' (SEQ ID N° 4) ear inf R n pGATtot
mutAT
KOATgapdhygr amplificati 5' TCTCCTTCAGCCTCGGAGAGTGGATCACGAGTAAG o inf F on 3' (SEQ ID N° 5)
selection
marker
KOATgapdhygr amplificati 5' TCCAGAGGAGGATCCGAACAAACGACCCAACACC 3' o inf R on (SEQ ID N° 6)
selection
marker
KOAT F amplificati 5' CAACGCCCAAGCACCGAACTCAATTCAC 3' (SEQ ID on KO N° 7)
cassette
KOAT R amplificati 5' TTCCTCCTTCCTTGCCTCATTCC 3'(SEQ ID N° 8) Primer name Primer Sequence
function
on KO
cassette
KOATCtrl F colony 5' CAGCAGAGACCATCTGCCTAGCAACTTC 3' (SEQ ID
PCR N° 9)
GAPD-775 R colony 5' GCCACTGCCATTGGAGATTG 3' (SEQ ID N° 10)
PCR
HygrolnsertCh colony 5' TTCGACAGCGTCTCCGACCTGAT 3' (SEQ ID N° 1 1) eck F PCR
KOATCtrl R colony 5' TGGTCTGGCCCTGAGTCTGAAG 3' (SEQ ID N° 12)
PCR
GAPDHygro15 high 5' GACATCCGATGTGTAGTTAATCA 3' (SEQ ID N° 15) 60 For fidelity
PCR
GAPDAT fusion CTTCGAGGAGTTTACAACCATTTGTGTAGAGTTGTTTT FusionB PCR TG (SEQ ID N°16)
GAPDAT fusion CAAAAACAACTCTACACAAATGGTTGTAAACTCCTCGA FusionC PCR AGG (SEQ ID N° 17)
GAPDAT fusion AAATGACTGACAACAATGGATTGGAAAGCCACAACTCC FusionD PCR (SEQ ID N° 18)
GAPDATterm fusion GAGTTGTGGCTTTCCAATCCCTCAAACAGTTCCTTCAA FusionE PCR TGC(SEQ ID N° 19)
GAPDAT high GCCTCGTCAACCATCTTATC (SEQ ID N° 20 )
FusionF fidelity
PCR
GAPDATterm fusion GCATTGAAGGAACTGTTTGAGGGATTGGAAAGCCACA RevFus PCR ACTC (SEQ ID N° 21)
P1 high AGAACAAGGCCGAGTATGTC (SEQ ID N° 22)
fidelity
PCR
URA3TK Rev fusion GTTAGCCTCCCCCATCTCCCTCATCTTGACTGAACTTT Primer name Primer Sequence
function
PCR TCTC (SEQ ID N° 23)
URA3TK For fusion GAAAAGTTCAGTCAAGATGAGGGAGATGGGGGAGGCT
PCR AAC (SEQ ID N° 24)
HygroCDS&T high TGAACAAACGACCCAACAC (SEQ ID N° 25)
Rev fidelity
PCR
GAPDAT fusion GGTGTTGGGTCGTTTGTTCACTCCAATGGCAGTGGCT ForFus short PCR TACC (SEQ ID N° 26)
ORF4URA3TK high GACGTTTCCAGGGACAACAG (SEQ ID N° 27) bp21 F fidelity
PCR
URA3TK fusion GGTAAGCCACTGCCATTGGAGTGAACAAACGACCCAA RevFus short PCR CACCC (SEQ ID N° 28)
GAPDAT fusion CAATTTCTTTTCTAGGAGTCATTTGTGTAGAGTTGTTTT FusionBbis PCR TG (SEQ ID N° 29)
GAPDAT fusion CAAAAACAACTCTACACAAATGACTCCTAGAAAAGAAA FusionCbis PCR TTG (SEQ ID N° 30)
ORF4URA3TK high GCCTTGGCGCTTGAGAAGTTCCC (SEQ ID N° 31) bp1 14F fidelity
PCR
P33 colony CCATACTCAAGCGCGAACAC (SEQ ID N° 32)
PCR
Ura3Un colony CAGCCTCTTCTAGTCCGCTCACAATTCC (SEQ ID N°
PCR 33)
P35 colony GAGCTCAAGACGCGTTTACTCAATGC (SEQ ID N° 34)
PCR
ATR colony CATGACAGCCTTTTCTTCTT (SEQ ID N° 35)
PCR Table 2. Ten best homology scores for the C. bombicola AT gene after a blastx homology search against all non-redundant protein sequences available at NCBI website.
Figure imgf000034_0001
3 GenBank Accession Number, b % Homology, c % Identity
Medium composition for the six different cultures used to evaluate the effect on the ratio of lactonic to acidic sophorolipids.
Reference Excess Excess YE 15 YE 1 No oil glucose g/L g/L citrate
Component Concentration (g/L)
Glucose 120 50 120 120 120 120
Yeast extract 4 4 4 15 1 4
Figure imgf000035_0001
Table 4 Composition of the PCR mix for fusion of two fragments. Both fragments are added in a molar ratio of 1 to 1.
Components Final concentration Volume
Milli-Q water Up to 50 μΙ
10x PfuUltra AD buffer 1x 5 μΙ
2 mM dNTP mix 0.25 mM 6.25
Fragment 1 max 25 ng/kb x μΙ
Fragment 2 max 25 ng/kb x μΙ
PfuUltra DNA polymerase 2.5 U 1 μΙ
Table 5 Fusion PCR cycling program.
Cycle Time Temperature
(°C)
1x 2 min 94
15x 30 s 94
PCR1 1 min Depending on
Tm Cycle Time Temperature
(°C)
1.5 min for first kb, 1 min for additional 72
kb
1x 7 min 72
1x 2 min 94
30x 30 s 94
PCR2 1 min Depending on
Tm
1.5 min for first kb, 1 min for additional 72
kb
1x 7 min 72
References
Altschul SF, Madden TL, Schaffer AA, Zhang JH, Zhang Z, Miller W, Lipman D (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
Asmer HJ, Lang S, Wagner F, Wray V (1988) Microbial production, structure elucidation and bioconversion of sophorose lipids. J Am Oil Chem Soc 65: 1460-1466.
Azim A, Shah V, Doncel GF, Peterson N, Gao W, Gross R (2006) Amino acid conjugated sophorolipids: a new family of biologically active functionalized glycolipids. Bioconjugate Chem 17: 1523-1529.
Banat IM, Franzetti A, Gandolfi I, Bestetti G, Martinotti MG, Fracchia L, Smyth TJ, Marchant R (2010) Microbial biosurfactants production, applications and future potential. Appl Microbiol Biotechnol 87: 427-444.
Casas JA, Garcia-Ochoa F (1999) Sophorolipid production by Candida bombicola:
Medium composition and culture methods. J Biosci Bioeng 88:488-494
Chen J, Song X, Zhang H, Qu YB, Miao JY (2006) Production, structure elucidation and anticancer properties of sophorolipid from Wickerhamiella domercqiae. Enzyme Microb Tech nol 39: 501-506 Davila AM, Marchal R, Vandecasteele JP (1992) Kinetics and balance of a fermentation free from product inhibition - sophorose lipid production by Candida bombicola. Appl Microbiol Biotechnol 38: 6-11.
Davila AM, Marchal R, Vandecasteele JP (1994) Sophorose lipid production from lipidic precursors - Predictive evaluation of industrial substrates. J Indust Microbiol 13:
249-257.
Davila AM, Marchal R, Vandecasteele JP (1997) Sophorose lipid fermentation with differentiated substrate supply for growth and production phases. Appl Microbiol Biotechnol 47:496-501.
Franzetti A, Tamburini E, Banat IM (2010) Applications of biological surface active compounds in remediation technologies. In Advances in Experimental medicine and biology Volume 672. Ramkrishna S (ed). Springer-Verlag Berlin: Germany; 121-134.
Gorin PAJ, Spencer JFT, Tulloch AP (1961) Hydroxy fatty acid glycosides of sophorose from Torulopsis magnoliae. Can J Chem 39: 846-855.
Gross R, Shah V (2004) Antimicrobial properties of various forms of sophorolipids.
International Patent WO 2004/044216 A1.
Gross R, Shah V (2005) Antifungal properties of various forms of sophorolipids US Patent US 2005/0164955 A1.
Hewald S, Josephs K, Bolker M (2005) Genetic analysis of biosurfactant production in Ustilago maydis. Appl Environ Microb 71 : 3033-3040.
Hewald S, Linne U, Scherer M, Marahiel MA, Kamper J, Bolker M (2006) Identification of a Gene Cluster for Biosynthesis of Mannosylerythritol Lipids in the Basidiomycetous Fungus Ustilago maydis. Appl Environ Micr 72 : 5469-5477.
Hommel RK, Weber L, Weiss A, Himmelreich U, Rilke O, Kleber HP (1994) Production of sophorose lipid by Candida (Torulopsis) apicola grown on glucose. J Biotechnol 33:147-155.
Hu YM, Ju LK (2001a) Purification of lactonic sophorolipids by crystallization. J Biotechnol
87: 263-272.
Hu YM, Ju LK (2001 b) Sophorolipid production from different lipid precursors observed with LC-MS. Enzyme Microbial Technol 29: 593-601. Imura T, Masuda Y, Minamikawa H, Fukuoka T, Konishi M, Morita T, Sakai H, Abe M and Kitamoto D (2010) Enzymatic conversion of unacetylated sophoroselipid into acetylated glucoselipid: surface-active properties of novel bolaform biosurfactants. J Oleo Sci 59: 495-501.
Kasture M, Singh S, Patel P, Joy PA, Prabhun AA, Ramana CB, Prasad BLV (2007) Multi utility sophorolipids as nanoparticle capping agents: synthesis of stable and water dispersible co nanoparticles. Langmuir 23 : 11409-1 1412.
Konishi M, Fukuoka T, Morita T, Imura T, Kitamoto D (2008) Production of new types of sophorolipids by Candida batistae. J Oleo Sci 57: 359-369.
Kralova I, Sjoblom J (2009) Surfactants used in food industry: a review. J Disper Sci Technol 30: 1363-1383.
Kulakovskaya T, Shashkov A, Kulakovskaya E, Golubev W, Zinin A, Tsvetkov Y, Grachev A, Nifantiev N (2009) Extracellular cellobiose lipid from yeast and their analogues: structures and fungicidal activities. J Oleo Sci 58: 133-140.
Kulakovskaya TV, Shashkov AS, Kulakovskaya EV, Golubev Wl (2004) Characterization of an antifungal glycolipid secreted by the yeast Sympodiomycopsis paphiopedili. FEMS Yeast Res 5: 247-252.
Kulakovskaya EV, Kulakovskaya TV, Golubev CI, Shashkov AS, Grachev AA, Nifantiev NE (2007) Fungicidal activity of cellobiose lipids from culture broth of yeast Cryptococcus humicola and Pseudozyma fusiformata. Russ J Bioorg Chem 33:
156-160.
Kurtzman CP, Price NPJ, Ray KJ, Kuo TM (2010) Production of sophorolipid biosurfactants by multiple species of the Starmerella (Candida) bombicola yeast clade. FEMS Microbiol Lett 311 : 140-146.
Lang S, Brakemeier A, Heckmann R, Spockner S, Rau U (2000) Production of native and modified sophorose lipids. Chim Oggi 18: 76-79.
Lemieux RU, Charanduk (1951) Biochemistry of the Ustilaginales. VI. The acyl groups of ustilagic acid. Can J Chem 29: 409-414.
Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C, Fong JH, Geer LY, Geer RC, Gonzales NR, Gwadz M, He S, Hurwitz Dl, Jackson JD, Ke
ZK, Lanczycki CJ, Liebert CA, Liu C, Lu F, Lu S, Marchler GH, Mullokandov M, Song JS, Tasneem AK, Thanki N, Yamashita RA, Zhang D, Zhang N, Bryant SH (2009) CDD: Specific functional annotation with the Conserved Domain Database. Nucleic Acids Res 37: 205-210. Mulligan CN (2009) Recent advances in the environmental applications of biosurfactants. Curr Opin Colloid In 14: 372-378.
Otto RT, Daniel HJ, Pekin G, Muller-Decker K, Furstenberger G, Reuss M and Syldatk C (1999) Production of sophorolipids from whey. II. Product composition, surface active properties, cytotoxicity and stability against hydrolases by enzymatic treatment. Appl Microbiol Biotechnol 52:495-501.
Rau U, Hammen S, Heckmann R, Wray V, Lang S (2001) Sophorolipids: a source for novel compounds. Ind Crop Prod 13: 85-92.
Saerens K, Van Bogaert I, Soetaert W, Vandamme EJ (2009) Production of glucolipids and specialty fatty acids from sophorolipids by Penicillium decumbens naringinase : Optimization and kinetics. Biotechnol J 4 : 517-524.
Saerens KM J, Roelants S, Van Bogaert INA, Soetaert W (2011) Identification of the UDP- glucosyltransferase gene UGTA1, responsible for the first gluvcosylation step in the sophorolipid biosynthetic pathway of Candida bombicola ATCC22214. FEMS Yeast Res 11 :123-132.
Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual, 3rd edition.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
Shah V, Doncel GF, Seyoum T, Eaton KM, Zalenskaya I, Hagver R, Azim A, Gross R (2005) Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities. Antimicrob Agents Chemother 49: 4093-
4100.
Spencer JFT, Gorin PAJ, Tulloch AP (1970) Torulopsis bombicola sp. n. A Van Leeuw J Microb Ser 36: 129-133.
Spoeckner S, Wray V, Nimtz M, Lang S (1999) Glycolipids of the smut fungus Ustilago maydis from cultivation on renewable resources. Appl Microbiol Biotechnol 51 : 33-
39.
Teichmann B, Linne U, Hewald S, Marahiel MA, Bolker M (2007) A biosynthetic gene cluster for a secreted cellobiose lipid with antifungal activity from Ustilago maydis. Mol Microbiol 66: 525-533.
Tulloch AP, Spencer JFT, Deinema MH (1968a) A new hydroxy fatty acid sophoroside from Candida bogoriensis. Can J Chem 46: 345-348.
Van Bogaert INA, De Maeseneire SL, Develter D, Soetaert W, Vandamme EJ (2008a) Cloning and characterisation of the glyceraldehyde 3-phosphate dehydrogenase gene of Candida bombicola and use of its promotor. J Ind Microbiol Biotechnol 35 : 1085-1092.
Van Bogaert INA, De Maeseneire SL, Develter D, Soetaert W, Vandamme EJ (2008b) Development of a transformation and selection system for the glycolipid producing yeast Candida bombicola. Yeast 25: 272-278.
Van Bogaert INA, Saerens K, De Muynck C, Develter D, Soetaert W, Vandamme EJ (2007) Microbial production and application of sophorolipids. Appl Microbiol Biotechnol 76: 23-34.
Zerkowski JA, Solaiman DKY (2007) Polyhydroxy fatty acids derived from sophorolipids.
J Amer Oil Chem Soc 84: 463-471.
Zerkowski JA, Solaiman DKY, Ashby RD, Foglia TA (2006) Head group-modified sophorolipids : synthesis of new cationic, zwitterionic, and anionic surfactants. J Surfactants Deterg 9 : 57-62.

Claims

Claims
1. A nucleic acid molecule consisting of the sequence as depicted by SEQ ID N° 1 encoding for an acetyltransferase, or a fragment thereof encoding for a protein retaining said acetyltransferase activity, or a variant thereof encoding for a protein having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
2. A polypeptide consisting of the amino acid sequence as depicted by SEQ ID N° 2 and having acetyltransferase activity, or a fragment thereof retaining said acetyltransferase activity, or a variant thereof having at least 50% sequence identity with SEQ ID N°2 and having said acetyltransferase activity.
3. Use of a nucleic acid molecule according to claim 1 having lost its capability to encode for a functional acetyltransferase, or, use of a polypeptide according to claim 2 having lost its acetyltransferase activity to produce a mixture comprising entirely unacetylated sophorolipids.
4. Use of a fungal species which is capable of producing sophorolipids to produce a mixture comprising entirely unacetylated sophorolipids wherein said fungal species has at least one mutation in a nucleic acid molecule according to claim 1 and wherein said mixture comprises at least 50% of entirely unacetylated sophorolipids.
5. Use according to claim 4 wherein said entirely unacetylated sophorolipids comprises at least or equal to 70% of lactonic sophorolipids.
6. Use according to any of claims 4-5 wherein said yeast species is selected from the group consisting of Candida bombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellata, Candida sp. NRRL Y- 27208, Rhodotorula bogoriensis, Wickerhamiella domericqiae and sophorolipid- producing species of the Starmerella clade.
7. Use according to claim 6, wherein said Candida bombicola is the strain Candida (Starmerella) bombicola ATCC 22214.
8. Use according to any of claims 4-7, wherein said mutation is a deletion and/or insertion and wherein said deletion and/or insertion results in a non-functional polypeptide.
9. A modified yeast strain belonging to a fungal species capable of producing sophorolipids , characterized in that said fungal strain, compared to an unmodified wild type strain : a) has at least one mutation in a nucleic acid molecule according to claim 1 , and b) produces a mixture of entirely unacetylated sophorolipids comprising at least 50% of entirely unacetylated sophorolipids.
10. Use of a polypeptide having acetyltransferase activity according to claim 2 to acetylate carbohydrates or carbohydrate-containing compounds.
1 1. Use of a modified host strain expressing a polypeptide having acetyltransferase activity according to claim 2 to acetylate carbohydrates or carbohydrate-containing compounds.
12. Use according to claim 11 wherein said modified host strain is transformed with an exogenous nucleic acid molecule according to claim 1 or wherein said modified host strain over-expresses an endogenous nucleic acid molecule according to claim 1.
13. Use according to claims 11-12, wherein said modified host strain is a bacterium, a fungus, a yeast cell, an insect cell, a plant cell or an animal cell.
14. Use according to claim13 wherein said yeast is Candida (Starmerella) bombicola ATCC 22214.
PCT/EP2011/072304 2010-12-15 2011-12-09 Producing unacetylated sophorolipids by fermentation Ceased WO2012080116A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10195091.3 2010-12-15
EP10195091 2010-12-15

Publications (1)

Publication Number Publication Date
WO2012080116A1 true WO2012080116A1 (en) 2012-06-21

Family

ID=43920852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/072304 Ceased WO2012080116A1 (en) 2010-12-15 2011-12-09 Producing unacetylated sophorolipids by fermentation

Country Status (1)

Country Link
WO (1) WO2012080116A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014079218A (en) * 2012-10-18 2014-05-08 Kao Corp Production method of glycolipid
EP2764006A4 (en) * 2011-10-04 2014-12-10 Politechnic Inst Univ New York MODIFIED SOPHOROLIPIDES FOR THE INHIBITION OF PHYTOPATHOGENS
WO2015028278A1 (en) * 2013-08-26 2015-03-05 Universiteit Gent Methods to produce bolaamphiphilic glycolipids
WO2015076423A1 (en) * 2013-11-21 2015-05-28 Kao Corporation Method for producing acetylated sphingoid base
WO2015153476A1 (en) * 2014-03-31 2015-10-08 The Regents Of The University Of California Methods of producing glycolipids
EP3327121A4 (en) * 2015-07-22 2019-01-02 Kao Corporation Mutant strain having high sophorolipid productivity
EP3327120A4 (en) * 2015-07-22 2019-01-16 Kao Corporation VARIANT WITH HIGH PRODUCTIVITY OF SOPHOLIPIDES
WO2019020578A1 (en) 2017-07-25 2019-01-31 Dsm Ip Assets B.V. Use of sophorolipids as feed additive
WO2023213677A2 (en) 2022-05-03 2023-11-09 Universiteit Gent Methods to produce acetylated and non-acetylated glycolipid amphiphiles
WO2025099076A2 (en) 2023-11-07 2025-05-15 Universiteit Gent Sble mutants with altered activity and sble homologues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044216A1 (en) 2002-11-06 2004-05-27 Polytechnic University Antimicrobial properties of various forms of sophorolipids
US20050164955A1 (en) 2003-11-06 2005-07-28 Gross Richard A. Antifungal properties of various forms of sophorolipids
WO2011061032A2 (en) * 2009-11-18 2011-05-26 Evonik Degussa Gmbh Cells, nucleic acids, enzymes, and use thereof, and methods for the production of sophorolipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044216A1 (en) 2002-11-06 2004-05-27 Polytechnic University Antimicrobial properties of various forms of sophorolipids
US20050164955A1 (en) 2003-11-06 2005-07-28 Gross Richard A. Antifungal properties of various forms of sophorolipids
WO2011061032A2 (en) * 2009-11-18 2011-05-26 Evonik Degussa Gmbh Cells, nucleic acids, enzymes, and use thereof, and methods for the production of sophorolipids

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
ALTSCHUL SF; MADDEN TL; SCHAFFER AA; ZHANG JH; ZHANG Z; MILLER W; LIPMAN D: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: doi:10.1093/nar/25.17.3389
ASMER HJ; LANG S; WAGNER F; WRAY V: "Microbial production, structure elucidation and bioconversion of sophorose lipids", J AM OIL CHEM SOC, vol. 65, 1988, pages 1460 - 1466, XP000566442
AZIM A; SHAH V; DONCEL GF; PETERSON N; GAO W; GROSS R: "Amino acid conjugated sophorolipids: a new family of biologically active functionalized glycolipids", BIOCONJUGATE CHEM, vol. 17, 2006, pages 1523 - 1529, XP008160841, DOI: doi:10.1021/bc060094n
BANAT IM; FRANZETTI A; GANDOLFI; BESTETTI G; MARTINOTTI MG; FRACCHIA L; SMYTH TJ; MARCHANT R: "Microbial biosurfactants production, applications and future potential", APPL MICROBIOL BIOTECHNOL, vol. 87, 2010, pages 427 - 444, XP019841587
BUCHOLTZ M L ET AL: "ACETYLATION OF 13 SOPHOROSYLOXY DOCOSANOIC-ACID BY AN ACETYL TRANSFERASE PURIFIED FROM CANDIDA-BOGORIENSIS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 251, no. 2, 1976, pages 424 - 430, XP002636236, ISSN: 0021-9258 *
CASAS JA; GARCIA-OCHOA F: "Candida bombicola:Medium composition and culture methods", J BIOSCI BIOENG, vol. 88, 1999, pages 488 - 494, XP008139506
CHEN J; SONG X; ZHANG H; QU YB; MIAO JY: "Production, structure elucidation and anticancer properties of sophorolipid from Wickerhamiella domercqiae", ENZYME MICROB TECHNOL, vol. 39, 2006, pages 501 - 506, XP025095215, DOI: doi:10.1016/j.enzmictec.2005.12.022
DAVILA AM; MARCHAL R; VANDECASTEELE JP: "Kinetics and balance of a fermentation free from product inhibition - sophorose lipid production by Candida bombicola", APPL MICROBIOL BIOTECHNOL, vol. 38, 1992, pages 6 - 11
DAVILA AM; MARCHAL R; VANDECASTEELE JP: "Sophorose lipid fermentation with differentiated substrate supply for growth and production phases", APPL MICROBIOL BIOTECHNOL, vol. 47, 1997, pages 496 - 501, XP003001802, DOI: doi:10.1007/s002530050962
DAVILA AM; MARCHAL R; VANDECASTEELE JP: "Sophorose lipid production from lipidic precursors - Predictive evaluation of industrial substrates", J INDUST MICROBIOL, vol. 13, 1994, pages 249 - 257, XP001070450, DOI: doi:10.1007/BF01569757
ESDERS T W ET AL: "Glucosyl- and acetyltransferases involved in the biosynthesis of glycolipids from Candida bogoriensis.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 10 MAR 1972 LNKD- PUBMED:5012313, vol. 247, no. 5, 10 March 1972 (1972-03-10), pages 1375 - 1386, XP002636235, ISSN: 0021-9258 *
FRANZETTI A; TAMBURINI E; BANAT IM: "Advances in Experimental medicine and biology", vol. 672, 2010, SPRINGER-VERLAG, article "Applications of biological surface active compounds in remediation technologies", pages: 121 - 134
GORIN PAJ; SPENCER JFT; TULLOCH AP: "Hydroxy fatty acid glycosides of sophorose from Torulopsis magnoliae", CAN J CHEM, vol. 39, 1961, pages 846 - 855, XP001070451, DOI: doi:10.1139/v61-104
HEWALD S; JOSEPHS K; B61KER M: "Genetic analysis of biosurfactant production in Ustilago maydis", APPL ENVIRON MICROB, vol. 71, 2005, pages 3033 - 3040, XP055009787, DOI: doi:10.1128/AEM.71.6.3033-3040.2005
HEWALD S; LINNE U; SCHERER M; MARAHIEL MA; KAMPER J; BÖLKER M: "Identification of a Gene Cluster for Biosynthesis of Mannosylerythritol Lipids in the Basidiomycetous Fungus Ustilago maydis", APPL ENVIRON MICR, vol. 72, 2006, pages 5469 - 5477
HOMMEL RK; WEBER L; WEISS A; HIMMELREICH U; RILKE 0; KLEBER HP: "Production of sophorose lipid by Candida (Torulopsis) apicola grown on glucose", J BIOTECHNOL, vol. 33, 1994, pages 147 - 155, XP023887395, DOI: doi:10.1016/0168-1656(94)90107-4
HU YM; JU LK: "Purification of lactonic sophorolipids by crystallization", J BIOTECHNOL, vol. 87, 2001, pages 263 - 272, XP002668738, DOI: doi:DOI:10.1016/S0168-1656(01)00248-6
HU YM; JU LK: "Sophorolipid production from different lipid precursors observed with LC-MS", ENZYME MICROBIAL TECHNOL, vol. 29, 2001, pages 593 - 601, XP055077472
HU YONGMEI ET AL: "Lipase-mediated deacetylation and oligomerization of lactonic sophorolipids.", BIOTECHNOLOGY PROGRESS, vol. 19, no. 2, March 2003 (2003-03-01), pages 303 - 311, XP002636234, ISSN: 8756-7938 *
IMURA T; MASUDA Y; MINAMIKAWA H; FUKUOKA T; KONISHI M; MORITA T; SAKAI H; ABE M; KITAMOTO D: "Enzymatic conversion of unacetylated sophoroselipid into acetylated glucoselipid: surface-active properties of novel bolaform biosurfactants", J OLEO SCI, vol. 59, 2010, pages 495 - 501
KAREN M.J. SAERENS ET AL: "One-step production of unacetylated sophorolipids by an acetyltransferase negative Candida bombicola", BIOTECHNOLOGY AND BIOENGINEERING, vol. 108, no. 12, 12 July 2011 (2011-07-12), pages 2923 - 2931, XP055027011, ISSN: 0006-3592, DOI: 10.1002/bit.23248 *
KASTURE M; SINGH S; PATEL P; JOY PA; PRABHUN AA; RAMANA CB; PRASAD BLV: "Multiutility sophorolipids as nanoparticle capping agents: synthesis of stable and water dispersible co nanoparticles", LANGMUIR, vol. 23, 2007, pages 11409 - 11412
KONISHI M; FUKUOKA T; MORITA T; IMURA T; KITAMOTO D: "Production of new types of sophorolipids by Candida batistae", J OLEO SCI, vol. 57, 2008, pages 359 - 369
KRALOVA; SJOBLOM J: "Surfactants used in food industry: a review", J DISPER SCI TECHNOL, vol. 30, 2009, pages 1363 - 1383
KULAKOVSKAYA EV; KULAKOVSKAYA TV; GOLUBEV CI; SHASHKOV AS; GRACHEV AA; NIFANTIEV NE: "Fungicidal activity of cellobiose lipids from culture broth of yeast Cryptococcus humicola and Pseudozyma fusiformata", RUSS J BIOORG CHEM, vol. 33, 2007, pages 156 - 160, XP019484085, DOI: doi:10.1134/S1068162007010189
KULAKOVSKAYA T; SHASHKOV A; KULAKOVSKAYA E; GOLUBEV W; ZININ A; TSVETKOV Y; GRACHEV A; NLFANTIEV N: "Extracellular cellobiose lipid from yeast and their analogues: structures and fungicidal activities", J OLEO SCI, vol. 58, 2009, pages 133 - 140
KULAKOVSKAYA TV; SHASHKOV AS; KULAKOVSKAYA EV; GOLUBEV WI: "Characterization of an antifungal glycolipid secreted by the yeast Sympodiomycopsis paphiopedili", FEMS YEAST RES, vol. 5, 2004, pages 247 - 252, XP004658876, DOI: doi:10.1016/j.femsyr.2004.07.008
KURTZMAN CP; PRICE NPJ; RAY KJ; KUO TM: "Production of sophorolipid biosurfactants by multiple species of the Starmerella (Candida) bombicola yeast clade", FEMS MICROBIOL LETT, vol. 311, 2010, pages 140 - 146, XP002636233, DOI: doi:10.1111/J.1574-6968.2010.02082.X
KURTZMAN CPPRICE NPJRAY KJKUO TM: "Production of sophorolipid biosurfactants by multiple species of the Starmerella (Candida) bombicola yeast clade", FEMS MICROBIOL LETT, vol. 311, 20 October 2001 (2001-10-20), pages 140 - 146, XP002636233 *
LANG S; BRAKEMEIER A; HECKMANN R; SPOCKNER S; RAU U: "Production of native and modified sophorose lipids", CHIM OGGI, vol. 18, 2000, pages 76 - 79
LEMIEUX RU; CHARANDUK: "Biochemistry of the Ustilaginales. VI. The acyl groups of ustilagic acid", CAN J CHEM, vol. 29, 1951, pages 409 - 414
MARCHLER-BAUER A; ANDERSON JB; CHITSAZ F; DERBYSHIRE MK; DEWEESE-SCOTT C; FONG JH; GEER LY; GEER RC; GONZALES NR; GWADZ M: "CDD: Specific functional annotation with the Conserved Domain Database", NUCLEIC ACIDS RES, vol. 37, 2009, pages 205 - 210
MULLIGAN CN: "Recent advances in the environmental applications of biosurfactants", CURR OPIN COLLOID IN, vol. 14, 2009, pages 372 - 378, XP026498522, DOI: doi:10.1016/j.cocis.2009.06.005
OTTO RT; DANIEL HJ; PEKIN G; MÜLLER-DECKER K; FURSTENBERGER G; REUSS M; SYLDATK C: "Production of sophorolipids from whey. II. Product composition, surface active properties, cytotoxicity and stability against hydrolases by enzymatic treatment", APPL MICROBIOL BIOTECHNOL, vol. 52, 1999, pages 495 - 501
RAU ET AL.: "Sophorolipids: a source for novel compounds", INDUSTRIAL CROPS AND PRODUCTS, vol. 13, 8 May 2001 (2001-05-08), pages 85 - 92, XP002636232 *
RAU U; HAMMEN S; HECKMANN R; WRAY V; LANG S: "Sophorolipids: a source for novel compounds", IND CROP PROD, vol. 13, 2001, pages 85 - 92, XP002668012, DOI: doi:10.1016/S0926-6690(00)00055-8
SAERENS K; VAN BOGAERT; SOETAERT W; VANDAMME EJ: "Production of glucolipids and specialty fatty acids from sophorolipids by Penicillium decumbens naringinase : Optimization and kinetics", BIOTECHNOL J, vol. 4, 2009, pages 517 - 524
SAERENS KMJ; ROELANTS S; VAN BOGAERT INA; SOETAERT W: "Identification of the UDP- glucosyltransferase gene UGTAI, responsible for the first gluvcosylation step in the sophorolipid biosynthetic pathway of Candida bombicola ATCC22214", FEMS YEAST RES, vol. 11, 2011, pages 123 - 132
SAMBROOK J; RUSSELL DW: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SHAH V; DONCEL GF; SEYOUM T; EATON KM; ZALENSKAYA; HAGVER R; AZIM A; GROSS R: "Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities", ANTIMICROB AGENTS CHEMOTHER, vol. 49, 2005, pages 4093 - 4100
SPENCER JFT; GORIN PAJ; TULLOCH AP: "Torulopsis bombicola sp. n.", A VAN LEEUW J MICROB, vol. 36, 1970, pages 129 - 133
SPOECKNER S; WRAY V; NIMTZ M; LANG S: "Glycolipids of the smut fungus Ustilago maydis from cultivation on renewable resources", APPL MICROBIOL BIOTECHNOL, vol. 51, 1999, pages 33 - 39, XP007921565, DOI: doi:10.1007/s002530051359
TEICHMANN B; LINNE U; HEWALD S; MARAHIEL MA; BÖLKER M: "A biosynthetic gene cluster for a secreted cellobiose lipid with antifungal activity from Ustilago maydis", MOL MICROBIOL, vol. 66, 2007, pages 525 - 533, XP002627542, DOI: doi:10.1111/j.1365-2958.2007.05941.x
TULLOCH AP; SPENCER JFT; DEINEMA MH: "A new hydroxy fatty acid sophoroside from Candida bogoriensis", CAN J CHEM, vol. 46, 1968, pages 345 - 348
VAN BOGAERT INA; DE MAESENEIRE SL; DEVELTER D; SOETAERT W; VANDAMME EJ: "Cloning and characterisation of the glyceraldehyde 3-phosphate dehydrogenase gene of Candida bombicola and use of its promotor", J IND MICROBIOL BIOTECHNOL, vol. 35, 2008, pages 1085 - 1092, XP019596386
VAN BOGAERT INA; DE MAESENEIRE SL; DEVELTER D; SOETAERT W; VANDAMME EJ: "Development of a transformation and selection system for the glycolipid producing yeast Candida bombicola", YEAST, vol. 25, 2008, pages 272 - 278
VAN BOGAERT INA; SAERENS K; DE MUYNCK C; DEVELTER D; SOETAERT W; VANDAMME EJ: "Microbial production and application of sophorolipids", APPL MICROBIOL BIOTECHNOL, vol. 76, 2007, pages 23 - 34, XP019538805, DOI: doi:10.1007/s00253-007-0988-7
ZERKOWSKI JA; SOLAIMAN DKY: "Polyhydroxy fatty acids derived from sophorolipids", J AMER OIL CHEM SOC, vol. 84, 2007, pages 463 - 471
ZERKOWSKI JA; SOLAIMAN DKY; ASHBY RD; FOGLIA TA: "Head group-modified sophorolipids : synthesis of new cationic, zwitterionic, and anionic surfactants", J SURFACTANTS DETERG, vol. 9, 2006, pages 57 - 62, XP001240226, DOI: doi:10.1007/s11743-006-0375-x

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764006A4 (en) * 2011-10-04 2014-12-10 Politechnic Inst Univ New York MODIFIED SOPHOROLIPIDES FOR THE INHIBITION OF PHYTOPATHOGENS
JP2014079218A (en) * 2012-10-18 2014-05-08 Kao Corp Production method of glycolipid
EP2910631A4 (en) * 2012-10-18 2016-06-22 Kao Corp PROCESS FOR PRODUCING GLYCOLIPIDS
US9540672B2 (en) 2012-10-18 2017-01-10 Kao Corporation Method of producing glycolipids
CN104736705B (en) * 2012-10-18 2017-12-22 花王株式会社 The manufacture method of glycolipid matter
WO2015028278A1 (en) * 2013-08-26 2015-03-05 Universiteit Gent Methods to produce bolaamphiphilic glycolipids
US9650658B2 (en) 2013-08-26 2017-05-16 Universiteit Gent Methods to produce bolaamphiphilic glycolipids
US10066249B2 (en) 2013-11-21 2018-09-04 Kao Corporation Method for producing acetylated sphingoid base
WO2015076423A1 (en) * 2013-11-21 2015-05-28 Kao Corporation Method for producing acetylated sphingoid base
WO2015153476A1 (en) * 2014-03-31 2015-10-08 The Regents Of The University Of California Methods of producing glycolipids
US10196663B2 (en) 2014-03-31 2019-02-05 The Regents Of The University Of California Methods of producing glycolipids
EP3327121A4 (en) * 2015-07-22 2019-01-02 Kao Corporation Mutant strain having high sophorolipid productivity
EP3327120A4 (en) * 2015-07-22 2019-01-16 Kao Corporation VARIANT WITH HIGH PRODUCTIVITY OF SOPHOLIPIDES
US10435684B2 (en) 2015-07-22 2019-10-08 Kao Corporation Sophorolipid highly-productive mutant strain
US10590428B2 (en) 2015-07-22 2020-03-17 Kao Corporation Sophorolipid highly-productive mutant strain
WO2019020578A1 (en) 2017-07-25 2019-01-31 Dsm Ip Assets B.V. Use of sophorolipids as feed additive
WO2023213677A2 (en) 2022-05-03 2023-11-09 Universiteit Gent Methods to produce acetylated and non-acetylated glycolipid amphiphiles
WO2025099076A2 (en) 2023-11-07 2025-05-15 Universiteit Gent Sble mutants with altered activity and sble homologues

Similar Documents

Publication Publication Date Title
WO2012080116A1 (en) Producing unacetylated sophorolipids by fermentation
Saerens et al. One‐step production of unacetylated sophorolipids by an acetyltransferase negative Candida bombicola
EP2580321B1 (en) Yeast strains modified in their sophorolipid production and uses thereof
US9102968B2 (en) Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids
US9650658B2 (en) Methods to produce bolaamphiphilic glycolipids
US10612063B2 (en) Methods and strains for producing bioproducts in Aureobasidium pullulans
EP2794865B1 (en) A lactonase derived from candida bombicola and uses thereof
Roelants et al. Biosurfactant gene clusters in eukaryotes: regulation and biotechnological potential
CN115916995A (en) Efficient Synthesis of ω-Glycosides and Alkyl Glycosides
US7285404B1 (en) Cyclic depsipeptide synthetase and method for recombinant production
US20100093060A1 (en) Growth of microorganisms in cellulosic media
US20250250535A1 (en) Methods to produce acetylated and non-acetylated glycolipid amphiphiles
JP2020000213A (en) Myo-inositol production method
KR101781259B1 (en) A method for production of gypenoside LXXV using ginsenoside glycosidase
US20080176300A1 (en) Microbial conversion of sugar acids and means therein
Class et al. Patent application title: YEAST STRAINS MODIFIED IN THEIR SOPHOROLIPID PRODUCTION AND USES THEREOF Inventors: Wim Soetaert (Lovendegem, BE) Wim Soetaert (Lovendegem, BE) Sofie De Maeseneire (Destelbergen, BE) Karen Saerens (Drongen, BE) Sofie Roelants (Gent, BE) Inge Van Bogaert (Overmere, BE) Assignees: UNIVERSITEIT GENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813325

Country of ref document: EP

Kind code of ref document: A1